top ad
Post Subject Author Posted On
777 NetworkNewsBreaks – Patriot One Technologies (TSX.V: PAT) (OTCQB: PTOTF) Scheduled to Attend Extraordinary Future Conference on September 20 Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) this morning announced that its management team will be presenting, exhibiting and participating in a panel session at the Extraordinary Future Conference on September 20, 2017, in Vancouver. The conference, presented by Cambridge House International, is expected to provide a tremendous opportunity for Patriot One to showcase its award-winning technology to the investment community. CEO Martin Cronin and Director Jeffery Tindale will both be in attendance and available in booth #3 for one-on-one meetings with prospective investors. Additionally, Cronin will be participating in a panel session on security and artificial intelligence at 10:30 a.m., as well as delivering an investor presentation in the Speakers Hall at 11:40 a.m. Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/19/2017 05:25:43 PM
776 NetworkNewsBreaks – PotNetwork Holding, Inc. (POTN) Announces Hurricane Irma Relief Promotion PotNetwork Holding, Inc. (OTC: POTN) this morning announced that electricity and internet service at Diamond CBD’s corporate headquarters have been restored, and its business is now back up and running smoothly in the wake of what meteorologists have classified as one of the largest recorded hurricanes to hit Florida. As part of the ongoing Hurricane Irma relief efforts, Diamond CBD will be donating 10 percent of all net proceeds for the next three days and offering a 50 percent discount storewide. “Our hearts go out to our community,” Gary Blum, CEO of PotNetwork Holding, stated in the news release. “You never expect to be blindsided by a natural disaster. We have committed to help our neighbors pick up the pieces by contributing 10% of net revenues generated over the next 3 days, as business resumes, and orders are placed for our 50% off hurricane relief promotion.” To take advantage of this promotion, customers should enter code ‘IRMA’ in the promo code selection box upon checkout at DiamondCBD.com. Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/19/2017 05:22:36 PM
775 NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Retains Consulting Services of Ben Paterson Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for scale-up, purification and manufacturing strategies related to the company’s cannabinoid biosynthesis program. Paterson brings nearly four decades of experience in developing pharmaceutical manufacturing and purification processes to the InMed team, having previously served as a senior engineering advisor with Pharmaceutical giant Eli Lilly and Company for nearly four decades. “Mr. Paterson brings significant experience in all facets of biosynthesis manufacturing and facility design,” Eric A. Adams, president and CEO of InMed, stated in the news release. “His expertise directing complex capital projects, overseeing facilities and equipment, and interfacing with various stakeholders will be a significant asset to InMed.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/19/2017 05:19:31 PM
774 At ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), Medicinal Cannabinoid Quality and Safety are Founding Principles - Producer of consistent, standardized medicinal cannabis - Menu of cannabis strains with varying CBD:THC ratios - ABcann’s CBD-Med is one of Canada’s highest-CBD products In an interview with Cantech Letter (http://nnw.fm/IOcj0), Aaron Keay, CEO of ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), talked about the factors that triggered the genesis of the company, one of Canada’s trailblazing producers of medicinal cannabis. Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available. Although, in general, not much of a bother to recreational users, to those using cannabis for pain relief or other medical purposes, this was causing a great deal of concern. Inconsistency in product quality makes the determination of optimal dosage levels impossible to achieve. As a result, “to deliver consistent, standardized medicinal cannabis that the public and patients can consistently rely on” became one of ABcann’s founding principles. That principle continues to guide the company to this day. The Canadian-licensed producer recently announced the release of one of Canada’s highest legal CBD:THC ratio cannabis products. This new product expands the range of therapies now available to patients and so increases the efficacy of current treatment regimens in the promising new field of cannabinoid therapies. At present, the majority of cannabinoid therapies are directed to alleviate the chronic pain resulting from a variety of maladies. Since delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are the cannabinoids occurring at the highest concentrations in cannabis, the therapeutic effects of the plant and its derivatives are most likely derived from these components acting alone or together. This is a line of research that has been explored successfully by GW Pharmaceuticals. The European company produces Sativex, a treatment for the relief of symptoms in patients with moderate to severe spasticity due to multiple sclerosis (MS), which contains a one-to-one ratio of THC to CBD. While many patients have found relief from pain in high-THC cannabis, a subset of these have reported short-term memory impairment, dysphoria (feeling uneasy for no apparent reason), increased levels of anxiety and even panic attacks. Fortunately, CBD is devoid of such malignant manifestations, exhibiting calming and uplifting properties that appear to mitigate the unwanted effects of THC. As a result, strains of cannabis that are rich in CBD, like those produced by ABcann, are most helpful to those averse or intolerant to THC and to patients who want pain relief without too much of a ‘high’. A look at the stats released by Health Canada will show where ABcann is on the CBD:THC ratio spectrum. Most cannabis strains (54%) on the Canadian market have a high CBD:THC ratio, with THC over 15% and CBD less than 1%. Many others (29%) have less THC but negligible amounts of CBD, with THC less than 15% and CBD under 1%. Only 14% of strains have both THC and CBD levels that exceed 5%, and just 3% of strains have less than 1% THC and more than 9% CBD, a highly prized category in which the latest ABcann strains can be found. Late last month, the company announced (http://nnw.fm/P3g5J) the release of its top-of-the-line CBD-Med, which has a ratio of 27.6:1 (18.5% CBD to 0.67% THC). This adds to ABcann current lineup of high-CBD products, which already include NC:Med, with 18.9% CBD to 1% THC and DC:Med, with 15.4% CBD to 1% THC. ABcann also expects to be able to sell oils from October 2017, a range that will include a 1:1 THC/CBD drop, a high THC dropper and a high CBD dropper. For more information, visit the company’s website at www.ABcann.ca Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/19/2017 05:16:30 PM
773 Greenkraft, Inc. (GKIT) is “One to Watch” - Greenkraft, Inc. expects to realize well over $1 million of new revenue in 2017 - Expansion plans include construction of larger manufacturing facility to accommodate increasing demand for Greenkraft’s alternative fuel commercial trucks - A new line of larger, heavy duty G3 and G4 commercial trucks are coming soon - Greenkraft vehicles meet EPA and CARB emission standards through use of clean alternative fuels Greenkraft, Inc. (OTCQB: GKIT) is a nationally recognized company specializing in the production of alternative fuel automotive products, including engines and commercial trucks. Located in Santa Ana, California, the company’s mission is to provide clean, green, energy efficient automotive products that have a price advantage coupled with unparalleled American performance. Established in 2008, Greenkraft, Inc. serves the commercial truck market powered by the alternative fuels CNG and LPG in classes 4, 5, 6 and 7. Greenkraft’s new line of trucks, known as the G3 and G4, will accommodate weights of 26,000 lbs. and 33,000 lbs., respectively. George Gemayel, CEO of Greenkraft, Inc., said the demand for larger trucks that run on alternative fuels continues to increase. “Greenkraft is going to revolutionize the trucking industry with these new 26,000 and 33,000 lbs. trucks that run on CNG and PROPANE fuel,” Gemayel states in a press release. “The only way we can meet increased demand for Greenkraft products is to expand our current factory. This expansion is one of many factors that will substantially increase the Company’s revenue in 2017.” Greenkraft produces a cab forward design for its commercial trucks, which allows the passenger area to be much larger than in other similar sized vehicles. Several tank capacity options exist, making it easy to select the most efficient model for a client’s specific needs. Greenkraft is one of the only companies in the world to offer a refrigeration option with an alternative fuel truck – an essential, must-have option for many businesses. Greenkraft trucks, considered among the best performing in the heavy-duty market, are used in a variety of industries and in some of the nation’s largest cities. The company also offers a line of trucks designed to run with a package from Allison Transmission Holdings, Inc. (NYSE: ALSN), which gives clients the option of purchasing a fully automatic transmission vehicle. This option expands the size of the driver pool since fully automatic shifting reduces driver fatigue, contributes to solving the issue of driver retention, and it is easy to use. CNG and LPG conversion systems made by Greenkraft are available for several major automobile brands including Ford, GM and Isuzu/GM. Installation, service, parts and warranty are all available through Greenkraft facilities and its partners. For more information, visit the company’s website at www.GreenkraftInc.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/19/2017 05:13:11 PM
772 What it Takes to Thrive in Canada’s Multi-Billion-Dollar Marijuana Industry NetworkNewsWire Editorial Coverage: Canadian medicinal marijuana sales could exceed $8 billion by 2024, as forecast by Canaccord Genuity Group’s November 2016 market research report. ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) (ABcann Profile) is considered one of Canada’s strongest growers, boasting a customer retention rate of 94.7 percent, no history of product recalls, and computer-controlled production that have strengthened the company’s reputation for its pharmaceutical-grade cannabis. While ABcann already occupies a strong position, its leadership team continues to draw on pharmaceutical and capital markets experience to help achieve broader corporate goals. These advantages separate ABcann from other producers such as Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF) and Aurora Cannabis Inc. (TSX: ACB) (OTCQX: ACBFF); led to a milestone financing agreement with investment firm Cannabis Wheaton Income Corp. (TSX.V: CBW) (OTC: KWFLF); and solidify the company’s position among high valuation companies like medical cannabis supply provider Aphria (TSX: APH) (OTC: APHQF). Experienced leadership is part of what has helped ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) earn its stripes in the marijuana industry. Under the helm of CEO Aaron Keay, ABcann became a publicly traded company in April 2017. Keay also exercised several warrants, adding $13 million to the company coffers of $48 million in working capital. Keay’s previous expertise in capital markets, including raising capital and overseeing finance and merger and acquisition transactions, gave him the ability to bring the company to the forefront of the Canadian medicinal marijuana industry and into the sights of Cannabis Wheaton (TSX.V: CBW) (OTC: KWFLF). On August 2, ABcann announced (http://nnw.fm/aVAL7) the close of an initial $15 million investment ($2.25 per share) by Cannabis Wheaton as part of a larger phased investment to fund an additional 50,000 square feet at ABcann’s second production facility at its 65-acre Kimmett property in Napanee, Ontario. Plans for this facility, in addition to the company’s current construction plans for a 100,000-square-foot purpose-built facility at the Kimmett property, position ABcann to expand at an unprecedented rate in the Canadian cannabis industry. Notably, Cannabis Wheaton’s valuation of ABcann comes at a 160% premium over the company’s current share price of $0.68. The cannabis streaming company based its valuation of ABcann on more than strong leadership, however. As stated earlier, ABcann’s history is void of any product recalls, unlike some major Canadian growers, and is reputed for its pesticide-free growing capabilities. As the company explores international opportunities, reputation for pharmaceutical-grade products is vital. In a press release announcing the release of one of Canada’s highest legal CBD:THC (cannabidol:tetrahydrocannabinol) ratio products available on the market, via its ABcann Medicinals, Inc. subsidiary, the company noted the importance of pesticide-free, high-quality production. “The development of these products is in line with ABcann’s corporate strategy as a premium product provider of organic, pesticide free cannabis,” Ken Clement, executive chairman of ABcann, stated (http://nnw.fm/MVa1v). “As the Company continues to scale production capacity, our product line will expand as we strive to increase shareholder value through capturing a larger market share of the current global medical markets.” Keay further emphasized the point in regard to the company’s global expansion strategies. “ABcann will continue to advance our core businesses and subsidiaries as production capacity continues to increase through our aggressive construction and expansion plans,” he said. “The construction timelines at both of our locations position ABcann to become a strong competitor in the existing global medical market and to take advantage of the emerging adult consumer market that is expected to emerge in 2018.” Even Keay’s recent decision to step down from his post as CEO (http://nnw.fm/cniW8) demonstrates considerable leadership. Keay will continue to contribute his experience in the capital markets to the company, working with incoming CEO Barry Fishman to move the company forward. Fishman will assume this role starting October 1, 2017. A business leader for nearly 20 years, Fishman served a nearly three-year role as CEO of Merus Labs (TSX: MSL), an international specialty pharmaceutical company – gaining invaluable expertise aligned with ABcann’s commitment to marketing the highest quality, pharmaceutical-grade cannabis. Under Fishman’s tenure, Merus saw a compound annual growth rate of over 50 percent and was purchased for about $342 million in July 2017. Fishman also served as CEO of Teva Canada and Taro Canada, vice president of Marketing at Ely Lilly, and is on the board of Aurora Cannabis. In addition to prime leadership, another key aspect of ABcann’s valuation is the fact that it owns the land housing its licensed production facilities. Notably, these facilities have the infrastructure to support scalable production in a computer-controlled environment, with precise control over air and water quality, temperature and humidity, and plant nutrition to ensure high product quality. The company operates a 14,500-square-foot Vanluven facility in Napanee, Ontario, which has an annual production capacity of 1,000 kg. The 71,000-square-foot Kimmett facility is currently under construction and is expected to add 20,000 kg of production capacity annually. Future expansion is planned on 65 acres of company-owned land, with an estimated 1.2 million square feet of development space and power, water, and waste infrastructure already in place. When understanding the tremendous opportunities in Canada’s marijuana market, it’s worth noting the growth story of Canopy Growth (TSX: WEED) (OTC: TWMJF), one of the biggest growers in the world, with more than half a million square feet of production space. The company saw its share prices skyrocket from C$2.20 at its IPO in May 2014 to a high of C$17.86 in November 2016, setting it up as Canada’s first billion-dollar marijuana stock. Canopy Growth recently moved to further solidify its expansion in New Brunswick with the acquisition of ACMPR applicant Spot Therapeutics, which, when licensed and fully expanded, will provide around 100,000 square feet of production space. The company also expanded its Smiths Falls and Bowmanville South footprints last quarter by 33% and 200%, respectively. Canopy is currently trading on the TSX exchange at C$10.27 per share, as of September 15, with a market cap of C$1.7 billion. Aurora Cannabis (TSX: ACB) (OTCQX: ACBFF), for which incoming ABcann CEO Fishman is a board member and independent director, has also taken a strong position in the Canadian market. Shares of the licensed Canadian grower climbed by more than 900 percent following its IPO, currently trading at C$2.64 with a valuation of $969 million. As the only licensed producer of medical marijuana in Alberta, Aurora operates a 55,200-square-foot cultivation and harvesting facility in the Rocky Mountains, and it is in the process of adding an additional 840,000 square feet across two other sites in Canada. Aurora owns a 19.9% stake in the first Australian company licensed to cultivate and conduct research on medical cannabis, and it owns a leading Germany-based wholesale importer, exporter and distributor of medical cannabis. Currently valued at C$884 million and trading at C$6.73, Aphria (TSX: APH) (OTC: APHQF) was the first publicly licensed producer to go cash flow positive from operations. The company produces capsules, vaporizers, and orally-administered cannabis oil droppers. In addition to addressing the demand for such products, a focus on safety, consistency, and the quality of patient care has contributed to the company’s rise. Aphria also has a strategy to expand into the growing U.S. medical cannabis market. Aphria currently trades at C$6.38 with a valuation of $885 million. Canada’s top growers are flourishing thanks to the country’s legalization of medical marijuana, and with recreational legalization set for July 2018, these producers are gearing up to take advantage of a forecast rise in recreational demand. Supported by $43 million in working capital, a strong leadership team of extensive pharmaceutical and capital markets expertise, and an enviable reputation for pharmaceutical-grade cannabis and cultivation technologies, ABcann has the potential to achieve a market valuation more closely aligned with its peers. With a market cap of C$83 million and trading at $0.84, ABcann may offer investors an attractively priced entry point into the burgeoning global marijuana industry. For more information on ABcann Global please visit: ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/19/2017 05:08:29 PM
771 Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects NetworkNewsWire Editorial Coverage: The hazards of pharmacology have hardly changed since Paracelsus, a famous Renaissance physician, astoundingly declared that it was only the dosage that separated a medicine from a poison, bundled with adverse side effects. Despite considerable advances in medicine, many medications are still as injurious as their Renaissance precursors. Nevertheless, recent developments in drug delivery technologies increasingly suggest that safer, more efficient treatment options are on the horizon. At the core of this potential are cannabinoids. Developments in this rapidly growing segment of the medical marijuana market are pioneered by a vast number of innovators, including Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) (LXRP Profile), GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals (NASDAQ: ZYNE), Cara Therapeutics (NASDAQ: CARA) and Philip Morris (NYSE: PM), all of which are invested in the cannabis space. Research findings in the cannabinoid field continue to astonish and elate. In August 2017, Lexaria Bioscience announced (http://nnw.fm/h7aG8) the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s high absorption TurboCBD™ product. The study will evaluate the effects of CBD on cardiovascular health and cognitive function. Lexaria’s TurboCBD, a brand of technologically enhanced, high absorption hemp oil capsules, came to market in March 2017. Its CBD content is fortified with high-quality American ginseng and ginkgo biloba for support of enhanced focus and memory, and reduced stress and fatigue. TurboCBD capsules contain a combination of CBD and minute quantities of long chain fatty acids like sunflower oil, utilizing a proprietary technology to create an amalgam that increases the ability of the human gastrointestinal system to absorb CBD. In vitro and human focus study testing has shown increases in CBD absorption using Lexaria’s technology by as much as 5-10 times more than conventional preparations. Those studies also demonstrated rapid onset of action in as little as 15 minutes. The TurboCBD study is designed to test a number of hypotheses expected to follow after its supplementation: (i) that circulating CBD and nitric oxide will increase in both young and old participants; (ii) that glucose and blood pressure will remain stable; and (iii) that vascular function, and cognitive and physical exercise performance will improve to a greater extent in older participants. The study will be conducted by researchers at the University of British Columbia, which has consistently been ranked as one of the top three universities in Canada. The institution is also considered one of the top research universities in the world and has conducted several earlier studies in the cannabis sector, available for review at http://nnw.fm/o8O9a. Lexaria has also developed and commercialized a patented and cost-effective delivery technology, DehydraTECH™, which has been both laboratory and market proven to enhance the performance of beneficial compounds in ingestible products across four categories: taste, smell, speed of action, and bio-absorption and bio-availability. At present, Lexaria is the only company in the world that has been awarded a patent for the improved (oral or ingestible, including pills) delivery of all non-psychoactive cannabinoids. Patents have been awarded in the U.S. and Australia and are pending in 40 more countries. This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs. Notably, because Lexaria’s technology is complimentary to all ingested forms of cannabinoids, the company is positioned to license its intellectual property to clinical-stage biotechnology companies, becoming an enabler – rather than a competitor – that works with other research and development pertaining to cannabinoids. Collaboration with a company like GW Pharmaceuticals (GWPH), for example, would could yield considerable outcomes. The British company, best known for its multiple sclerosis (MS) cannabinoid product, Sativex, is working feverishly to bring another to market. Currently, its lead cannabinoid product candidate Epidiolex is in phase III clinical trials. This drug is a proprietary oral solution of pure plant-derived cannabidiol (CBD) for the treatment of severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS). Also developing treatments for epileptic conditions, with rather less encouraging outcomes than GW Pharmaceuticals, is Zynerba Pharmaceuticals (ZYNE). In August 2017, the company published disappointing results of phase II studies of its cannabidiol (CBD) product, ZYN002, aimed at treating adult epilepsy patients with focal seizures. Since CBD has shown some promise in reducing epileptic seizures, as in the GW Pharmaceutical studies, this raises the possibility that Zynerba’s setback may be due, not to the payload, but the delivery system. ZYN002 employs a transdermal gel that is applied topically on the surface of the skin. However, an oral delivery system, like the one developed by Lexaria, may prove more effective. Cara Therapeutics (CARA) is another biotech now coming to terms with disappointing clinical trial results. Trials for an oral formulation of its drug candidate CR845, an opioid derivative, studied in osteoarthritis patients, did not turn out so well. However, the study tested patients on low dosages (1.0 mg and 2.5 mg) of CR845 taken orally. Higher oral dosages and CR845 taken intravenously have shown more promising outcomes. The company’s research into opioids has spilled over into cannabinoids. Current preclinical research involves CR701, a cannabinoid receptor agonist, designed to treat chronic pain. The incentive to develop cannabinoid products to treat chronic pain is driven, in part, by the opioid epidemic. While opioid overdose deaths are in the tens of thousands, there appears to be no clearly documented account of anyone dying from an overdose of marijuana. Smoking marijuana is, of course, one method proven to deliver cannabinoids effectively. Alas, the now well-known deleterious effects on the respiratory system are spurring efforts to develop other delivery mechanisms, such as non-smoke cigarettes, which perhaps is why Philip Morris International (PM) invested $20 million in Israeli startup Syqe Medical. The company manufactures delivery devices for cannabis, like its inhaler. Syqe’s pocket-sized Inhaler delivers precision dosages of its payload: 100 micrograms, every time the device is activated. This overcomes a major barrier to adoption of medical cannabis by doctors: the lack of standardization in dosage regimens. Syqe has tested a similar device in hospitals in a clinical trial that demonstrated its dosing precision superiority to other modes of THC administration. With Philip Morris’ involvement, nicotine may just be next. As the research into cannabinoids continues to unearth excitingly novel ways to treat a variety of medical conditions, delivery systems are proving to be just an important as payloads. As a result, companies with advanced delivery systems, like Lexaria, are likely to find cannabinoid biotechs beating that proverbial path to their door. For more information on Lexaria Bioscience please visit: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/19/2017 05:02:51 PM
770 NetworkNewsBreaks – Global Payout, Inc. (GOHE) Subsidiary Attends Cannabis World Congress & Business Exposition Payment solutions company Global Payout, Inc. (OTC: GOHE) this morning announced that executive management members of its majority-owned subsidiary, MoneyTrac Technology, Inc., successfully represented the company at the fourth annual Cannabis World Congress & Business Exposition held in Los Angeles. “Representation at events such as this present such a unique and powerful opportunity to grow our presence and establish new partnerships within an industry that is incredibly tight-knit and yet growing at an unprecedented rate,” MoneyTrac COO Vanessa Luna stated in the news release. “I am encouraged by the many different connections we established during this expo, and I am optimistic about the likelihood of a decent number of them possibly materializing into new partnerships for our company at some point in the near future.” MoneyTrac is currently making arrangement to ensure representation for the expo’s East Coast dates from October 4-6 in Boston. As noted in the news release, this will “present another opportunity for the Company to promote and create awareness for the effective technology and other industry-specific services and solutions [it offers] to businesses operating in the cannabis industry.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/18/2017 05:22:36 PM
769 NetworkNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Nets Total Proceeds of $11.9 Million from Exercise of Warrants ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced that it has received total proceeds of nearly $11.9 million from the exercise of an aggregate of 19,185,965 warrants since the closing of its acquisition of ABcann Medicinals Inc. on April 28, 2017. With these funds, ABcann’s current cash position stands at approximately $45 million, giving the company the means to execute previously outlined plans to expand its production capabilities. “ABcann thanks our shareholders for their continued support and confidence as we work toward expanding our facilities and increasing production,” Aaron Keay, director and CEO of ABcann, stated in the news release. “Our strong financial position, represented by our current cash position is earmarked for new construction and will facilitate the timely execution of our business plan. The Company’s main focus in the coming months will be on the deployment of capital towards the expansion of our existing Vanluven facility and development and construction of the new Kimmett facility, as well as the pursuit of our international expansion plans.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/18/2017 05:19:15 PM
768 NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Provides Update on Data Showing Effectiveness of THC in Addressing Underlying Cause of Alzheimer’s India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model. Per the update, the aggregation of Aβ protein in the cerebral cortex and hippocampus, which is believed to be a primary cause of Alzheimer’s disease, is decreased by as much as 40 percent when treated with varying concentrations of THC. “As Alzheimer’s progresses, synaptic dysfunction and the death of neurons lead to memory loss,” Ram Mukunda, CEO of IGC, stated in the news release. “These study results, when combined with the earlier reported data that shows IGC-AD1 reduces Aβ40 and Aβ42 production by as much as 50%, and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease.” Based on these findings, IGC intends to position IGC-AD1 as a drug that can be used both as a treatment for Alzheimer’s and as a prophylactic treatment for the prevention of Alzheimer’s. The company intends to commercialize a supplement version of IGC-AD1 to be sold as a medical dispensary product. Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/18/2017 05:15:23 PM
767 NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Subsidiary Completes China FDA Filing; Moves toward Launch of Hemp-Infused Skin Care Line Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX), through wholly-owned subsidiary CBD Biotechnology Co. Ltd., this morning announced that it has completed the record filing process with the China Food & Drug Administration (“CFDA”) for its first line of non-industrial hemp-infused skin care products. Following this milestone, the company expects to launch its ‘CBD Magic Hemp Series’ skin care line in the next couple of months, effectively positioning CBD Biotechnology as a leader in what the company has called “an untapped segment of China’s skin care industry.” “I am very pleased to announce the upcoming launch of CBD Biotechnology’s non-industrial hemp-infused skin care line, CBD Magic Hemp Series,” Summer Yun, CEO of CBD Biotechnology, stated in the news release. “We have not only completed the filing process with CFDA, but we have also contracted with a large processing factory in Shanghai, China, with over 14-years of experience in cosmetics production.” Upon launch, the initial CBD Magic Hemp Series product line is expected to include a brightening and refreshing moisturizer, a perfecting shield primer and a peptide collagen solution. Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/18/2017 05:11:23 PM
766 India Globalization Capital, Inc. (NYSE: IGC) Reports Promising Progress of Cannabis-Based Alzheimer’s Drug Candidate - IGC is the only publicly traded cannabis stock with patent filings for treating Alzheimer’s disease - Company has a first-mover advantage in phytocannabinoid-based combination therapy - Alzheimer’s is America’s most expensive disease, costing the country an estimated $259 billion in 2017 It is considered America’s most expensive disease, projected to cost an estimated $259 billion in the United States in 2017 and as much as $1.1 trillion by 2050 (http://nnw.fm/Owr4D). It is not cancer, and it is not AIDS. It is Alzheimer’s disease. This devastating chronic neurodegenerative disease is the most common cause of dementia among older adults and is the sixth-leading cause of death in the U.S. There is currently no cure for Alzheimer’s disease, nor are there presently any effective treatments to slow the disease or reverse its effects, but India Globalization Capital, Inc. (NYSE MKT: IGC) is working to change that. In a recent press release (http://nnw.fm/Hi96k), IGC discussed its progress on IGC-ADI, a drug candidate that is cannabis-based and targeted at lessening some of Alzheimer’s worst symptoms. IGC-ADI works through a molecular pathway that permits low doses of tetrahydrocannabinol (THC) to do five things: Inhibit Aβ protein production Inhibit Aβ protein aggregation Reduce protein phosphorylation Restore mitochondria function Redirect the immune system Amyloid beta peptide (Aβ) is a protein believed to cause the formation of plaque in the cerebral cortex and hippocampus, causing lesions. Alzheimer’s disease is believed to be caused by two different types of lesions—the first being senile plaque that is made up of amyloid beta peptides (Aβ plaque) and the second being neurofibrillary tangle, which is composed of highly phosphorylated Tau protein. Aβ proteins are normally cleared away through biological processes, but, in Alzheimer’s patients, these proteins are unregulated and build up into insoluble fibroles. Senile plaques and extracellular misfolded oligomers resultantly form and are believed to be toxic to nerve cells in the brain. It has been found that IGC-AD1 may inhibit the production of amyloid beta peptide. In a recent press release, IGC provided an update on in vitro data compiled from genetically engineered cell lines, which has been confirmed by IGC Senior Advisor Dr. Chuanhai Cao, who is also an associate professor of pharmaceutical sciences at the University of South Florida’s College of Pharmacy. The data shows that at varying THC concentrations, production of Aβ40 protein decreases by as much as 50 percent over a 48-hour time period. Aβ40 and Aβ42 play a central role in amyloid plaques and have been implicated in the pathogenesis of Alzheimer’s disease. Dr. Cao’s studies at USF led to the filing of a patent by USF entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” IGC has since acquired the exclusive rights to the patent filing, and the company intends to advance the technology through medical trials, with the ultimate aim of bringing relief to Alzheimer’s sufferers. IGC is currently the only publicly traded cannabis stock to have patent filings for a potential breakthrough Alzheimer’s treatment. This gives the company a first-mover advantage in phytocannabinoid-based combination therapy, as discussed in a recently published article featuring IGC and four other standout companies that are currently seeking to find viable treatments for Alzheimer’s (http://nnw.fm/2R5Eo). For more information, visit the company’s website at www.IGCInc.us Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/18/2017 05:07:54 PM
765 ProBility Media’s (PBYA) One Exam Prep Division Enters Asset Purchase Agreement with Contractor Exam Preps - Acquisition of Contractor Exam Preps of Pittsboro, North Carolina, would give One Exam Prep access to new markets, customers - One Exam Prep is already on pace to have 70% gain in year-over-year revenues - Chris Barrow, president of Contractor Exam Preps, would join One Exam Prep division as a master instructor ProBility Media Corp. (OTCQB: PBYA), through its One Exam Prep division, has entered into an asset purchase agreement (http://nnw.fm/2UcRm) with Contractor Exam Preps of Pittsboro, North Carolina. The acquisition would expand One Exam Prep’s markets and customers. ProBility Media is an EdTech company which offers the skilled trades high quality training courses, eLearning opportunities and materials. The firm is seeking to build an international brand for educating, training and compliance for the skilled trades. It serves small businesses, as well as enterprise-level corporations. In a news release, Noah Davis, president and COO of ProBility, said, “With sales on pace to exceed a 70% increase year-over-year, combined with the anticipated addition of Contractor Exam Preps, One Exam Prep is poised to enter new markets and offer more to its current and new customers than ever before.” Chris Barrow, president of 20-year-old Contractor Exam Preps, would join One Exam Prep as a master instructor, per the purchase agreement. “We are very much looking forward to integrating Barrow’s expertise and skill sets into One Exam Prep,” said Rob Estell, founder and president of One Exam Prep. “We currently service 22 states and offer hundreds of high-quality online courses, private e-tutoring, application processing, daily physical classes, and all of the training materials, at very competitive pricing.” Employer-based formal training in the U.S. is a $177 billion annual market, according to a ProBility presentation within an 8K SEC filing (http://nnw.fm/I3D7a). The Trump administration’s infrastructure plans call for an increase in apprenticeships to five million from 40,000 today. Some 60% of the jobs created by the $1 trillion plan will require less than six months of training. ProBility offers educational and compliance materials for 60 skilled trades in 15 categories. The diverse list of subjects includes electrical, solar, glass glazing, plumbing, air conditioning, irrigation, pollutant storage, and others. It is targeting annual organic revenue growth of 25-30% and 20-25% additional sales through acquisitions, the presentation shows. Further, it is targeting a 30% EBITDA margin. For more information, visit the company’s website at www.ProBilityMedia.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/18/2017 05:03:59 PM
764 HighCom Global Security, Inc. (HCGS) Serves a Global Market with a Focus on Quality Management - HighCom’s blast protection products are ISO 9001:2008 certified and meet the quality standards of BA 9000 - The company has manufactured over a million plates with no operational failures or recalls - In Q2 2017, it reported a 116 percent increase in year-over-year revenues, with $1.5 million earned over a three-month period HighCom Global Security, Inc. (OTC: HCGS), a leader in blast effects mitigation solutions, has introduced several new products in 2017, while continuing to uphold its ISO 9001:2008-certified Quality Management System. This system has been in place since 2005 and was certified the following year. It helps assure approval of all products by the International Organization for Standardization (ISO). HighCom works to meet the basic requirements and continually make improvements. Its plates, helmets, shields, and other types of armor; bullet proof vests; ballistic blankets; and other offerings also adhere to the armor quality standards of BA 9000 certification, established by the National Institute of Justice (NIJ). The company serves law enforcement, military and government customers, as well as those in the commercial sector. It can offer fire suppression for naval vessels and merchant ships. Products are also available to help protect buildings against vehicle-delivered bombs. In addition, the company supplies a line of rifle armor, civilian armor systems, vest attachments, and bags and pouches. Just this year, several new products were introduced, including a lightweight and high-performance soft armor panel (the Level IIIa elite) and multi-curve, hard armor ballistic plate (the Level III++). Four new hard armor products were added in February, which have been recognized by the NIJ’s Compliance Testing Program. In terms of body armor, it is the only standard that has been nationally accepted. HighCom’s total of 11 hard armor and five soft armor solutions are certified to the institute’s high quality standards. Since its founding in February 1997, the company has served a large and diverse market. Over about a decade, it distributed nearly one million pieces of ballistic armor via Department of Defense contracts, and it has capacity to output more than 20,000 pieces of armor each month. This high level of performance doesn’t seem to be slowing down. In a recent news release (http://nnw.fm/Fhg99), HighCom Global Security reported a year-over-year increase of 116 percent for Q2 revenues. The company reported revenue of $1.5 million for the quarter, and $2.6 million for the first half of the year, which marked a 37.5 percent increase over the first half of 2016. Its continued success is in part due to an ability to serve the global defense market and adhere to leading standards, but HighCom’s own technical development strategy also plays a role. A ballistic testing laboratory at the company’s Columbus, Ohio R&D center and manufacturing plant is where soft body armor, shields, tactical armor systems, helmets, and other products are developed and quality controlled. Here, testing guarantees 100 percent effectiveness, according to the company, and includes the same tests conducted at NIJ-approved ballistic labs worldwide. For more information, visit the company’s website at www.HighComGlobal.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/18/2017 04:59:41 PM
763 NetworkNewsBreaks – University of British Columbia to Conduct Clinical Study of Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Game-Changing Oral CBD Product While cannabidiol and other marijuana-derived substances are traditionally smoked, this can cause damage to the lungs, and edible cannabis products have their drawbacks, too—typically being filled with sugars or other sweeteners to mask the unpleasant flavor associated with cannabis compounds. With its pioneering TurboCBD™ product, however, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral CBD intake, having engineered the product to enhance absorption through the intestinal tract without active compounds being destroyed by stomach acid or broken down by the liver, and this revolutionary product also masks the unpleasant flavor of cannabis compounds. An article further discussing this topic reads: “In August 2017, the University of British Columbia (UBC) announced (http://nnw.fm/3GYyd) that it will conduct the first clinical study of the high-absorption product while evaluating its effects on cognitive function and cardiovascular health of human volunteers. Currently, Lexaria is the only company to have been awarded a patent for delivery of ingestible non-psychoactive cannabinoids. It holds patents in the U.S. and Australia, and more are pending in over 40 other countries. The upcoming UBC study will be double-blind and placebo controlled. Researchers will measure the effects after a single dose and after seven days of daily doses. The 24 volunteers will consist of young and old individuals, whose glucose, blood pressure, vascular function, cognition, and physical performance will be measured. Blood samples, exercise tests, heart rate, respiration, and neuropsychological tests, among other measurements, will be conducted as well. These tests will provide a complete set of pharmacokinetic and pharmacodynamic performance data of Lexaria’s TurboCBD™.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/15/2017 05:09:24 PM
762 NetworkNewsBreaks – AppSwarm, Inc. (SWRM) Leverages Growth Strategy by Focusing on Key Revenue Streams Building on $589,000 in revenue earned in 2016, AppSwarm, Inc. (OTC: SWRM) is going strong in 2017 with a vigorous growth strategy that is centered on a proprietary business model, known internally as the “Swarm.” This strategy involves measures like in-house development and assets gained through mergers and acquisitions. An article further discussing this topic reads: “The four key revenue streams driving the company’s progress include the incubation of apps, using completion of concept and development, market analysis, sales/marketing, and financial management services. AppSwarm is also highly engaged in social game development. It has developed highly relevant concepts internally, although it has also been successful in purchasing and redeveloping existing games and applications. Focusing on specialty niches has boosted revenue as well, especially casino and role-playing movie-themed applications. Several projects have involved partnerships leveraging technology and market expertise, allowing the company to apply each product to the specific market in an appropriate way.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/15/2017 05:06:32 PM
761 NetworkNewsBreaks – Algae Dynamics Corp. (ADYNF) Collaborates with Prominent Neuroscientist to Research Cannabinoid Potential in Treating Mental Health Disorders Algae Dynamics Corp. (OTCQB: ADYNF), a Canadian company engaged in developing proprietary research as well as products derived from cannabis and hemp oils, has commenced a collaborative relationship with Dr. Laviolette, a neuroscientist at the University of Western Ontario, Canada, who is examining the treatment potential of cannabinoids in addressing disorders like addiction, schizophrenia, depression and post-traumatic stress disorder. Dr. Laviolette has been seeking ways to more effectively utilize chemicals found in marijuana to treat some of these illnesses, while Algae Dynamics has been taking a holistic approach by examining specific cannabinoids found in marijuana and combining that research with expertise in extracting various nutritional dietary products, like Omega-3 fatty acids. An article further discussing this topic reads: “Emerging research shows that Omega-3 fatty acids can have very strong interactions with the brain’s natural or biological endocannabinoid system and can also modulate the effects of cannabinoids on the brain. If there is a dietary deficiency of Omega-3 fatty acids, the brain’s natural cannabinoid system is not going to work with optimal efficiency,” Dr. Laviolette explained. “’By contrast, if you can supplement with Omega-3 fatty acids you see certain improvements in the brain’s cannabinoid system, so that immediately got us interested in how synergies between Omega-3 fatty acids and cannabinoids that are derived from marijuana might serve as potential, novel pharmaceutical and nutraceutical products for treating certain specific mental health disorders.’ The brain’s natural cannabinoid system is involved in a lot of different processes that relate to mental health, including mood regulation, one’s ability to learn and remember, and certain cognitive tasks.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/15/2017 05:04:03 PM
760 NetworkNewsBreaks – Recent Competitor Recalls Illustrate Importance of ABcann Global’s (TSX.V: ABCN) (OTCQB: ABCCF) Innovative, Pesticide-Free Cannabis Growth Practices Recently, the Canadian government announced that Broken Coast Cannabis Ltd. was recalling several products sold in 2016 due to the discovery of two banned pesticides in random samples, and several other Canadian cannabis growers have also had product recalls this year after banned pesticides were discovered in their products during mandatory testing. Instances like these serve to further illustrate the importance of the controlled, pesticide-free medical marijuana growth practices of ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF), which continues to meet product demand through its Napanee, Ontario, production facility and is also moving forward with expansion plans. An article further discussing this topic reads: “ABcann has moved methodically through each stage of our growth since first obtaining our license in 2014,” founder and director Ken Clement said in an update published on the ABcann website. “Providing a high quality, standardized pesticide-free product to our patients remains our number one priority as we initiate our largest expansion plans to date.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/15/2017 05:00:40 PM
759 ProBility Media Corp. (PBYA) Professional e-Learning and Training Addressing Rising Demand for Skilled Labor - ProBility now offers leading vocational educational materials in 60+ fields, including the electrical, construction, plumbing and security industries - An overwhelming majority of technical employers are struggling to find workers with the appropriate skills - Technical high schools are simulating workplaces to prepare students for their careers in historically underprivileged areas Access to technology-based education resources is becoming open to more people. Even as the National Center for Education Statistics reported about 20.5 million students (fall 2016) were enrolled in colleges and universities throughout the U.S., career training and advancement materials are becoming more available to those looking for jobs requiring skilled labor. ProBility Media Corp. (OTCQB: PBYA) is a growing brand serving the training requirements for several different technical fields. In many of these, 95 percent of employers are having trouble finding workers with the right skills in 2017, based on U.S. Chamber of Commerce data published in a recent report (http://nnw.fm/Fe8zJ) on skilled labor demand. Thanks to several recent acquisitions, ProBility can now provide study materials for electricians, construction workers, contractors, and plumbers, as well as many other skilled trades. The company provides access to all the latest NEC National Electrical Codes, with books, reference guides, and digital media available on CD and DVD. It has also reached into the public safety market. The launch of ProBility Safety Academy means training is open to those looking to advance their potential in public safety, private security, criminal justice, and police science. The need for vocational training services is reaching from coast to coast. High school teachers and students alike are benefiting. In fact, technical high schools are cropping up in places like Huntington, West Virginia, as a recent New York Times article pointed out (http://nnw.fm/xTD3Y). Four teachers at a summer training program worked on a miniature boiler similar to larger counterparts found at power generating plants. The educational programs they’re preparing for will simulate workplaces and include everything from vocational training to random drug testing, to get students familiarized with work environments and prepared for future careers. Simulated workplaces also have real-world equipment, ranging from drafting tables and welding torches to stethoscopes and 3D printers. Laser engraving equipment and professional software are expected to be used, from leading brands like AutoDesk Inventor. As part of the program, students will also get breaks during the day as employees working for technical organizations do. ProBility is focused on providing a one-stop resource. Therefore, small- and medium-sized businesses can access e-learning resources, so they can offer employees training and career advancement opportunities. Its efforts to provide a single source of training materials does not stop at the borders of the United States. The recent acquisition of Cranbury International extends the company’s e-learning reach into the Caribbean, Mexico, Columbia, Brazil, and other countries in Central and South America. For more information, visit the company’s website at www.ProBilityMedia.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/15/2017 04:56:53 PM
758 ChineseInvestors.com, Inc. (CIIX) Sets Goal of Greater than 100% Gain in FY2018 Revenues - In FY2017, the company’s investor relations business grew 130%, and its subscriptions business rose by 57% - Warren Wang, founder and chief executive officer of CIIX, sets goal of greater than 100% gain in sales in FY2018 and cost-cutting to achieve profitability - Company excited about its expansion of auxiliary services into the digital currency industry; Wang says that market will offer long-term opportunities ChineseInvestors.com, Inc. (OTCQB: CIIX) recorded a skyrocketing 76% year-over-year operating revenues increase for its fiscal year ended May 31, 2017. The company’s two divisions exhibited double-digit and triple-digit growth in FY2017. The investor relations business grew 130%, while the subscriptions business rose 57% during the 2017 fiscal year, the company reported (http://nnw.fm/UF4Gn). Total sales grew to $1,667,977 in FY2017 compared to $948,385 the prior year. Warren Wang, founder and chief executive officer of CIIX, says the company’s goal is more than a 100% jump in FY2018 sales, while cutting costs and achieving profitability. The primary reason for the increase in sales for the two divisions was a decision by management to be more discerning in deciding which companies would receive its investor relations services. Also, the firm placed itself on a more cash compensation basis — resulting in more sales — rather than taking equity compensation. CIIX has a goal of becoming the primary Chinese medical cannabis publicly traded company. It is focused on the R&D and distribution of legalized, hemp-based cannabidiol (CBD) to the global Chinese-speaking community. It maintains an online store in the free trade zone of Shanghai, China, and plans on opening a brick-and-mortar outlet in San Gabriel, California. Before the end of 2017, CIIX plans to launch a cryptocurrency education and trading subscription service and the first Chinese daily video news broadcast from the NYSE covering digital currency and blockchain technology. It has also established CBD Biotechnology Co., Ltd., as a wholly-owned subsidiary in Shanghai, China. It launched OptHemp, its first hemp oil product line. In the coming months, the company said, it will unveil in China its first hemp-infused skin care product line. “I am very pleased about the Company’s significant increase in revenue in the fiscal year ended May 31, 2017,” Warren Wang, founder and chief executive officer of CIIX, stated in a news release. “Although the blueprint of our Company’s business strategy has expanded through its entrance into the Hemp Industry, our core subscription and investors relations services remain strong with significant growth rates. I am thankful for the investors who have supported our ongoing development plans and look forward to a prosperous year ahead.” For its non-industrial hemp-based products, the company has engaged Scottsdale, Arizona-based Launch Haus LLC to help it in its direct response marketing, digital, e-commerce and direct sales channels. In addition, the company has thus far realized $2 million through August 29, 2017, from its private placement of some 10 million shares of its Series D-2017 convertible preferred stock, priced at $1 per share. For more information, visit the company’s website at www.ChineseInvestors.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/15/2017 04:42:53 PM
757 NetworkNewsBreaks – Bollente Companies, Inc. (BOLC) Reaches Millennials with trutankless® Smart Water Heater System Bollente Companies, Inc.’s (OTC: BOLC) trutankless® water heaters are likely to be more appealing to tech savvy millennials than more traditional models, as they can be managed from anywhere in the world using a smartphone. An article further discussing this topic reads: “The trutankless smart water heater system can be managed by logging in to a customizable online control panel. From the dashboard, residential and commercial users can obtain real-time status reports, adjust unit temperature settings, view up to three years of water usage data and change notification settings from anywhere in the world, using a computer or web-enabled smart device. Additionally, service professionals can use the dashboard to monitor system status on every unit they install, allowing them to proactively contact their customers if a service or warranty appointment is needed. The smartphone apps, which allow monitoring and control of the tankless systems, are available for download from the Google Play and Apple iOS stores.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/14/2017 06:27:17 PM
756 NetworkNewsBreaks – PotNetwork Holding (POTN) Subsidiary Secures More Than $200,000 in Sales at Recent Trade Show Diamond CBD Sales, a subsidiary of PotNetwork Holding, Inc. (OTC: POTN), attained more than $200,000 in sales at the Big Industry Trade Show in New York on August 10-11. An article further discussing this topic reads: “In addition to the $200,000 at the BIG Industry Trade Show, Diamond CBD also generated sales of more than $320,000 at the Market Week Event, held in Las Vegas. Late in July, the firm also recorded revenues of some $300,000 at the CHAMPS trade show in Las Vegas, PotNetwork Holding said.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/14/2017 06:23:58 PM
755 NetworkNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Modifies JV Approach to Enter Strategic Markets in China In an effort to expand more rapidly in China, Moxian, Inc. (NASDAQ: MOXC) has shifted the focus of its joint venture strategy, including the agreement with Shewn International Group of Shanghai. An excerpt of an article further discussing this topic reads: “Moxian, Inc. has changed its business strategy to grow more quickly within China, targeting the nation’s top four markets while also beginning to utilize a joint venture strategy in order to penetrate these markets more efficiently with the aid of entrenched businesses. MOXC’s marketing and sales team members are now acting as sales managers, working with independent agents to secure higher volume.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/14/2017 06:21:05 PM
754 NetworkNewsBreaks – ORHub, Inc. (ORHB) Enlists ICHOM in Effort to Advance Value-Based Health Care Model Health care software-as-a-service company ORHub, Inc. (OTC: ORHB) today announced that it has become a Technology Affiliate of the International Consortium for Health Outcomes Management (“ICHOM”), a non-profit organization focused on advancing value-based health care through the standardized measurement and reporting of patient outcomes. ICHOM is expected to aid ORHub’s ongoing efforts to facilitate a shift toward a value-based health care model by developing and promoting the adoption of core outcome sets that focus on meaningful indicators of patient functional outcomes, including health-related quality of life, mobility and pain levels following treatment. “Our mission is to improve value, which should be defined by the outcomes achieved relative to the cost of delivering those outcomes,” Wesley Mitchell, chief technology officer of ORHub, stated in the news release. “As a technology company, we’ve been effective in figuring out the true cost of surgical procedures, but we needed an independent organization to define the standard for quality.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/14/2017 06:16:58 PM
753 AppSwarm, Inc. (SWRM) Targeting Revenues of $6-7 Million by FY2018 - SWRM restructures as one company with two divisions, capitalizing on synergies between MediaPlay and Incubation and Acquisition Development - Ron Brewer, CEO and director, forecasts significant revenue growth in FY2017, cites strong initial revenues in FY2016 - New management team at SWRM, with extensive acquisition experience, is seasoned in growing emerging companies AppSwarm, Inc. (OTC: SWRM), under its new management team, has restructured as one company split into two divisions, and management hopes to achieve revenues of $6-7 million by FY2018, Ron Brewer, the company’s CEO and director, noted in a recent news interview (http://nnw.fm/RmZ4l). AppSwarm is an application acceleration company in the multi-platform games industry that engages in joint ventures, acquisitions and international opportunities. It now has two divisions. One is MediaPlay, targeting opportunities internationally and focused on joint venture efforts and larger projects, such as supplying TV channels with services. MediaPlay is an international multi-platform games publisher and developer acquired in mid-August by SWRM. The other division is Incubation and Acquisition Development (IAD), which is focused on the incubation program and direct acquisitions, as well as gaming opportunities, interactive development and e-commerce business solutions to enhance SWRM’s organic growth. SWRM’s management team may be new, but it is very experienced in business management, the mobile games market, achieving joint ventures, licensing and aiding games developers as an incubator. Brewer, who joined SWRM last year, has served as managing director of Southbridge Advisory Group since 1990. Southbridge is a boutique firm focused on management services and M&A. John Rabbitt, SWRM’s CFO and director, has an extensive and diverse business background, having held positions at The Pillsbury Company and PepsiCo. In addition, Chris Gray, president of the studios at MediaPlay, is a 30-year veteran of the video game industry. Steve Wall, president of publishing at MediaPlay, is a 23-year industry veteran who founded or co-founded five game companies and oversaw the launch of greater than 600 games. “We want to get both divisions fully launched and out in market,” Brewer said in the interview. “We see a possibility, probability, and our managers are wanting to forecast for 2018 somewhere between $6 million and $7 million in revenue.” For more information, visit the company’s website at www.App-Swarm.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/14/2017 06:13:33 PM
752 InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Builds Moat around Proprietary Biosynthesis Technology - Proprietary biosynthesis process to produce cannabinoids - Provisional patent application filed - Cost-effective methodology to produce trace cannabinoids If you have any doubt that InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is on the right track as it moves to protect its biosynthesis technology for cannabinoids, then a word from a famed figure may make you change your mind. Known worldwide for his investing prowess, Warren Buffett has said, “I don’t want a business that’s easy for competitors. I want a business with a moat around it with a very valuable castle in the middle” (http://nnw.fm/ILqd2). Naturally, the Sage of Omaha was referring to an economic moat and not its tangible water-filled counterpart. One obvious way of constructing such an economic moat would be by registering a patent, which is exactly what InMed is planning to do. The company, which specializes in the research and development (R&D) of novel, cannabinoid-based drug therapies, has announced the filing of a provisional patent application for its proprietary biosynthesis process for the manufacture of cannabinoids that are identical to those found in nature (http://nnw.fm/lGxK8). This filing is the first step in setting up defenses. Under U.S. patent law, a provisional patent application filed with the United States Patent and Trademark Office (USPTO) allows the filer to get a filing date and book a place in the queue. But, just as importantly, it affords protection for up to 12 months without filing a complete patent application. The provisional application may later be converted into a non-provisional one or be replaced by a regular patent application. The process in Canada, although not the same, is very similar. To obtain protection outside North America, the Patent Cooperation Treaty (PCT) offers one streamlined route. The PCT procedure facilitates a patent application in all contracting states that are signatories with one filing, obviously a boon, since 145 sovereign states are members of the PCT. The PCT process allows the filing of an “international patent application,” which acts as an initial application for a patent in any member country. However, an “international patent application” never matures into an “international patent”. No such animal exists. A PCT filing simply reduces the burden of individual filings to contracting states and acts as a patent application to the contracting state in which the patent is meant to go into effect. Patents are issued by sovereign states and are always limited to national boundaries. InMed’s provisional patent application will protect the biosynthesis process it has developed for the production of cannabinoids. In itself, biosynthetic production of chemicals is nothing new, but it really took off in 1978 after Genentech succeeded in modifying Escherichia-coli (E-coli) bacteria to produce synthetic insulin, a breakthrough credited with saving thousands of lives. Insulin is required by diabetics, whose bodies either do not produce the hormone or handle it inefficiently, in order to absorb glucose. In its absence, blood sugar increases to levels that may damage internal organs. Before biosynthesis, insulin was produced from the pancreas of pigs and cows in a costly, rather inhumane process. InMed’s biosynthesis technology involves a process that can be applied to manufacture all the naturally occurring cannabinoids, through which the DNA of the cannabinoid to be produced is applied to Escherichia-coli (E-coli) bacteria. The E-coli DNA is then removed, leaving just the cannabinoid DNA, which can then replicate and multiply. This process combines the inherent safety and known efficacy of the natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process. InMed’s biosynthesis methodology will likely be used to produce the less naturally occurring phytocannabinoids such as delta-8 tetrahydrocannabinol (Δ8 THC), cannabidivarin (CBDv), and tetrahydrocannabivarin (THCv), although, for the present, the company is not saying. Regardless of which cannabinoid castles InMed decides to build, they will all be protected by a sturdy economic moat. For more information, visit the company’s website at www.InMedPharma.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/14/2017 06:08:50 PM
751 Innovative Cannabis Players Offer Promising Entry into Explosive Market NetworkNewsWire Editorial Coverage: It is no secret that the legal marijuana market is exploding in North America. Analysts have predicted the cannabis market in the United States could reach $24.1 billion by 2025, and recent polls indicate 61 percent of Americans now believe marijuana use should be federally legalized1. Measures are currently being taken in Canada to legalize recreational marijuana by 2018. On a global scale, the worldwide cannabis market has been projected to reach up to $55.8 billion USD by 20252. A wide variety of players have been scrambling to stake a claim in this booming market, whether through directly handling the marijuana plant or by serving those who do. Unique standouts in this burgeoning market include ChineseInvestors.com, Inc. (CIIX) (CIIX Profile), CV Sciences, Inc. (CVSI), Terra Tech Corp. (TRTC), Medical Marijuana, Inc. (MJNA) and Hemp, Inc. (HEMP). ChineseInvestors.com, Inc. (CIIX) is tapping into a profitable niche market as it serves Chinese-speaking consumers throughout the world and aims to become the largest publicly traded Chinese medical marijuana company. CIIX is focused on the research, development and distribution of legalized cannabidiol (CBD) to the global Chinese-speaking community. Already one of the fastest growing segments in the U.S. hemp and legal marijuana industry, application of CBD is also gaining traction in China. CIIX operates an online store in the free trade zone of Shanghai, China, where CBD sales are legal, though marijuana use is not. CIIX also recently established, through its wholly owned subsidiary ChineseHempOil.com, Inc., a club-style Hemp Education Center in the company’s home market of San Gabriel, California, to educate interested parties regarding the potential health benefits of non-industrial hemp and hemp-derived CBD (http://nnw.fm/oV4Ga). CIIX recently engaged Arizona-based Launch Haus LLC, a holding company that specializes in digital direct-to-consumer marketing and product branding, to aid in growing the company’s worldwide sales of hemp-based CBD products (http://nnw.fm/RVz21). In June 2017, the company further incorporated CBD Biotechnology Inc. in British Columbia, Canada, as part of its efforts to enter the medical marijuana market there. Medical marijuana has been federally legal in Canada since 2001, and the Canadian government is now making strides toward the national legalization of recreational marijuana. “The incorporation of CBD Biotechnology Inc. is a promising step forward toward CIIX’s goals to enter the medical marijuana industry. Through its expansion into Canada, CIIX aims to generate significant revenues through sales of CBD-based health products, while helping the nearly one million Chinese in Canada to improve their overall health,” Warren Wang, founder and CEO of CIIX, stated in a news release (http://nnw.fm/9y0Dc). In December 2016, CIIX entered into a wholesale agreement with a well-known CBD health brand and formally launched a website for its subsidiary, ChineseCBDoil.com, which went live in January 2017. This launch marked the introduction of the world’s first Chinese language online store for CBD health products. At that same time, CIIX debuted the first Chinese language Yelp-style social media app where users can discuss and review cannabis services and products, as well as find locations of dispensaries. The company has built a widespread user base of more than 100,000 individuals, and it continues its focus on investing in both the R&D and distribution of CBD products. Corporate objectives include plans to further its study into the effectiveness of CBD for medicinal purposes in an effort to become the first company in China to employ CBD oil as a means of mitigating the suffering of epilepsy and Alzheimer’s patients. The application period for such new drugs in China is only two to four years—significantly shorter than the time it often takes companies to fulfill regulatory requirements in the United States. As CIIX continues to penetrate new markets, others are taking notice. Consilium Global Research recently projected a CAGR of almost 100 percent for CIIX through 2026 (http://nnw.fm/e5EiK), predicting revenues of up to $14.8 million. Another standout cannabis player is CV Sciences, Inc. (CVSI), which operates two distinct divisions: pharmaceuticals and consumer products. The company’s pharmaceuticals division is focused on the development and commercialization of novel therapeutics that utilize synthetic CBD. Its consumer products division manufactures, markets and sells plant-based CBD products to various market sectors, distributing these products nationally through the Internet as well as through health food stores and health care provider offices. The company’s divisions are backed by a medical and scientific advisory board, as well as state-of-the-art production facilities, and its consumer products are supported by formal safety reviews, increasing case reports and recommendations from physicians. CV Sciences is pursuing FDA approval for drugs with particular indications, featuring CBD as the active pharmaceutical ingredient, and the company has achieved promising preclinical results. CV Sciences’ initial drug candidate is CVSI-007, a chewing gum that contains nicotine and synthetic CBD to aid individuals in quitting tobacco use and escaping addiction. Vertically integrated, cannabis-focused agricultural company Terra Tech Corp. (TRTC) is another interesting marijuana play, operating through various subsidiaries including Blüm, IVXX Inc., Edible Garden and MediFarm LLC. Three of these subsidiaries are cannabis-focused. Blüm operates retail and medical cannabis facilities that deliver high-quality medical marijuana products to patients seeking alternative treatments for chronic medical conditions, as well as premium cannabis for Nevada’s adult-use market. IVXX, Inc. produces cannabis-extracted products for regulated medical marijuana dispensaries throughout California and adult-use and medical cannabis dispensaries in Nevada. Under the IVXX brand, Terra Tech recently filed a patent with the U.S. Patent and Trademark Office for cannabis-infused rolling papers, which are anticipated to be released in 2018. The company’s MediFarm LLC subsidiaries are focused on medical and adult-use cultivation and permitting businesses in Nevada. Medical Marijuana, Inc. (MJNA) stood out as the first company to offer hemp-based CBD products in the United States. The company accomplished this by offering cannabis-derived products that exploit the health properties of non-psychoactive cannabinoids, like CBD, which are legal in the U.S. The company uses cannabis varieties (hemp) that are grown outside the U.S. and either have very low tetrahydrocannabinol levels or no THC at all. Carefully cultivated CBD hemp oil and hemp oil products, offering a full range of phytocannabinoids and high CBD content, are created and then imported into the U.S. In addition to being the first publicly traded cannabis company in the U.S., MJNA has stood out as the first company to bring legal medical cannabis products to Mexico, Brazil, Puerto Rico and Paraguay; the first company to offer government-subsidized botanical cannabis-based products; the first company to deliver prescription CBD products to treat epilepsy, Alzheimer’s, Parkinson’s, chronic pain and migraine; the first company to deliver cannabis brands across U.S. state lines and international borders; and more. Hemp, Inc. (HEMP) is an industrial hemp-focused company that aims to become a leader in the industrial hemp market through a portfolio of synergistic businesses formed through purchase, acquisition or joint venture with companies across various hemp industry sectors. Hemp, Inc.’s mission is to offer green solutions through its hemp products, which are eco-friendly and can often be used in place of petroleum-based products. The American hemp fiber industry has been estimated at over $500 million, and a hemp crop is known to be more economical and ecological than cotton or trees, reducing water, energy and pesticide use. Hemp, Inc.’s products include DrillWall lost circulation material for oil field drilling application and Spill-Be-Gone and SpillSuck for large- and small-scale oil spill cleanup. The company is also developing SpillMaster for offshore oil spill cleanup. For investors seeking play in the cannabis market, the mentioned companies offer intriguing and varied opportunities. As this burgeoning market continues its forward drive, these companies may provide promising opportunities to climb aboard. Editorial Sources: 1) CBS News: http://nnw.fm/5Qh2x 2) Grand View Research: http://nnw.fm/Gf3dQ For more on CIIX please visit: ChineseInvestors.com (CIIX) or www.ChineseInvestors.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/14/2017 06:05:09 PM
750 Industry Leaders Find Success in Subscription-Based Business NetworkNewsWire Editorial Coverage: Thanks to subscription-based business models, consumers are not left to wonder what the best buying decisions may be. Companies that offer subscriptions can provide customers with a multitude of services bundled together, whether the product is streaming television programs, design or sales software, or purchasing and managing lottery tickets. On the corporate side, subscription services have enabled companies to be more flexible and scalable toward their offerings while providing them with greater, more predictable revenue. LottoGopher Holdings (OTCQB: LTTGF) (CSE: LOTO) (FRA: 2LG) (LottoGopher Profile) is one example of a company that has succeeded with its subscription model. Targeting the 80 million consumers in the U.S. who purchase lottery tickets regularly, LottoGopher offers daily, monthly and annual subscriptions to customers in California, with plans to scale up its presence in 22 other states over the next few years. This service builds on the success of large providers such as Netflix, Inc. (NASDAQ: NFLX) and Amazon.com, Inc. (NASDAQ: AMZN), as well as software companies Adobe Systems, Inc. (NASDAQ: ADBE) and Salesforce.com, Inc. (NYSE: CRM). As a lottery messenger service cognizant of consumer demand for convenience, LottoGopher Holdings (LTTGF) enables people to buy lottery tickets legally in California, at the same price as at a store, with a debit or credit card. Featured on NBC, CNN, CBS News, ABC and Fox News, and in Forbes, Time and the Los Angeles Times, the company is an increasingly recognizable brand. The company’s success and anticipated growth are anchored to the conveniences that it offers to subscribers. LottoGopher subscribers maintain an account balance, which is updated after each drawing, while the system secures tickets directly from the lottery retailer. The emerging company has seen positive signs during its testing period. Among visitors to the site, 7 percent provided their email address, 43 percent of those who signed up via email became members, and 12 percent of freemium plan members converted to paid memberships. The company’s goal is to create a subscriber base of approximately half a million paying members by 2020 in an effort to achieve nearly $50 million in annual revenues — a mission that accompanies its plan to expand its reach into 22 other states. As the subscription numbers grow, LottoGopher continues to adjust its features to address the modern consumer. Most recently, the company announced its ongoing integration of a payment processing solution that will allow members to pay via bitcoin and Ethereum. “In the past few months we have seen an uptick in subscriptions and we want to continue this momentum. By making it as convenient as possible for our members to order Powerball, Mega Millions and SuperLotto Plus, we are continuing the mission to really target millennials. Integrating with a solution that accepts digital currencies is part of this ongoing strategy,” James Morel, founder and CEO of LottoGopher, stated in the news release (http://nnw.fm/2RisV). “In short order we will have the processing ability to accept bitcoin and ether, a safer, quicker and anonymous way to transact in this new digital-driven day and age.” LottoGopher members can currently purchase lottery tickets via the LottoGopher website, making “lost” lottery tickets a thing of the past. They can also receive alerts, strategies and access to lottery news, and they can play individually or pool winnings as members of public or private groups online. Strategic partnerships play an important role in LottoGopher’s business model. Its Lottoland partner has been ranked as one of Britain’s Top 30 fastest-growing companies, per a Financial Times FT1000 Report. Since first offering its online lottery services in 2013, Lottoland has achieved $357 million USD in annual sales, marking a revenue increase of 820 percent between 2012 and 2015 (http://nnw.fm/2Z8xT). Like many other companies in the subscription space, LottoGopher sees exponential potential. The company’s niche in this space enables it to secure a spot in the $70 billion U.S. lottery industry, which is 4x the size of the sports industry and 10x larger than the music industry. Another solid example of the potential of paid subscription services is Netflix, Inc. (NFLX), which sells subscriptions rather than the individual movies available in its catalog. As an aside, it is worth noting that, while movie subscription sales have far outpaced those at the box office, lottery tickets sales exceeded movie ticket purchases sevenfold, according to a 2015 CNN report. With Netflix, members pay a monthly fee and can watch as few or as many movies, TV shows, documentaries and Netflix originals as they want. This same model is applied by LottoGopher; in fact, the model is so comparable that even the monthly subscription rates are similar – at around $8 to $12 per month. In Q2 2017, membership for the streaming service grew from 99 million to 104 million, while revenue grew 29.6 percent year-over-year. Netflix offers an array of additional features that keep its subscribers on deck. The streaming service lets users play, pause, rewind and resume watching, and there are no commercials. Also, content can be downloaded to computers, tablets, and mobile devices. The company also offers other bonuses to customers, such as a one month free trial for new members. Amazon.com, Inc. (AMZN) also offers a successful, recognizable subscription service. Launched in the U.S. in 2005, its Amazon Prime service offered perks such as free shipping. Since then, Amazon has added video and music streaming services, access to books, audio content, games, and photo storage under the Prime brand. Members also receive rewards bonuses by using Amazon Reward or Prime Store cards, and even paying with debit through the Amazon Prime Reload program. According to Statista (http://nnw.fm/5hgHw), subscribership for Amazon Prime reached about 85 million in July 2017, compared to 41 million in March 2015. Consumer Intelligence Research Partners has also discovered that subscription members spend more than non-members (about $1,300 compared to $700 per year). On average, Prime members are privier to spending and tend to be more loyal customers. Adobe Systems, Inc. (ADBE), a leader in cloud-based design software, reported approximately $1.77 billion in revenue for its best second quarter in its history, while subscription revenue increased 37 percent for the quarter to $1.48 billion. Roughly four years ago, Adobe distanced itself from the traditional sales model and, in a move that initially generated considerable consumer backlash, instead offered its solutions in a variety of packages ranging from $20-$50 a month. As noted in a recent Motley Fool article, the decision to keep course on the subscription-based business model has positioned Adobe for continued success (http://nnw.fm/fq59A). Salesforce.com, Inc. (CRM) is a leader in enterprise and CRM software, in the second quarter of fiscal 2018, becoming the first enterprise software company to break $10 billion in revenues. Focused on subscription cloud services that perform the same functions as traditional, costly in-house systems, the company realized a 26 percent annual increase in subscription and support revenues. Revenues for that segment were $2.37 billion, accounting for the majority of total second-quarter revenues of $2.56 billion. Salesforce has demonstrated how software-as-a-service and pay-as-you-go models can yield impressive numbers, and expects full-year fiscal 2018 revenue to increase between 23-24 percent to $10.3 billion to $10.4 billion. The above leaders are prime examples of how subscription sales can generate income over the long term and in a variety of consumer applications. As LottoGopher continues to evolve its offerings to meet consumer demands, the company can look to the success stories of industry behemoths such as Netflix, Amazon, Adobe and Salesforce to carve its own unique spot in the subscription-based space via the $70 billion lottery market. For more information on LottoGopher, please visit: (LottoGopher Holdings) Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/14/2017 06:00:10 PM
749 NetworkNewsBreaks – Global Payout, Inc. (GOHE) Subsidiary Enters Letter of Intent with BlazeNow, Inc. Payment solutions company Global Payout, Inc. (OTC: GOHE) this morning announced that its majority owned subsidiary, MoneyTrac Technology, Inc., has executed a Letter of Intent with BlazeNow, Inc., a majority owned subsidiary of MediaTechnics Corporation (OTC: MEDT). BlazeNow, once called the “Yelp” of the cannabis industry by NY Daily News, is an advertising and data collection platform focused on connecting cannabis-related businesses with patients and customers. “We are excited to lay the groundwork for what we believe will be a very productive business partnership with BlazeNow,” Vanessa Luna, COO of MoneyTrac Technology, stated in the news release. “The goals are to leverage this partnership in pursuing joint revenue products and services. Through this LOI, we hope to establish a joint-venture partnership with BlazeNow so that we can pool each of the industry-specific resources we have available to help significantly grow both brands.” This morning’s announcement follows the recent launch of BlazeNow’s new app on both Android and iOS platforms, a milestone that’s expected to strategically position the brand for collaborative efforts with MoneyTrac Technology as it looks to achieve broader expansion initiatives. Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/13/2017 05:25:53 PM
748 Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia - The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product - TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x - The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract, without active compounds destroyed by stomach acid or broken down by the liver, the product also masks the flavor of compounds with undesirable tastes. In August 2017, the University of British Columbia (UBC) announced (http://nnw.fm/3GYyd) that it will conduct the first clinical study of the high-absorption product while evaluating its effects on cognitive function and cardiovascular health of human volunteers. Currently, Lexaria is the only company to have been awarded a patent for delivery of ingestible non-psychoactive cannabinoids. It holds patents in the U.S. and Australia, and more are pending in over 40 other countries. The upcoming UBC study will be double-blind and placebo controlled. Researchers will measure the effects after a single dose and after seven days of daily doses. The 24 volunteers will consist of young and old individuals, whose glucose, blood pressure, vascular function, cognition, and physical performance will be measured. Blood samples, exercise tests, heart rate, respiration, and neuropsychological tests, among other measurements, will be conducted as well. These tests will provide a complete set of pharmacokinetic and pharmacodynamic performance data of Lexaria’s TurboCBD™. Regarding the expected outcome of the study, professor Philip Ainslie, PhD, stated in the recent report, “…To quantify the pharmacokinetics of TurboCBD™ will allow us to make informed recommendations of optimum dosing in order to improve vascular health and performance throughout healthy aging. Once we understand these processes better, the applications to various clinical populations can then be explored…” Details of the test results are expected to be released once the study is completed and the data are interpreted. According to Lexaria, its “plant-to-bloodstream” product amplifies intestinal absorption by 5-10x. It uses fatty acids, which combine with the active pharmaceutical ingredient to block them from bitter taste receptors on the tongue. Active ingredients are protected by lipids as they pass through the stomach. In the small intestine, long chain fatty acids are absorbed directly into the lymphatic system, while medium chain fatty acids are absorbed via the liver. An August 2015 in vitro absorption study, conducted in a third party lab, found a 499 percent increase in CBD bioabsorption in the intestines. A human focus study in March 2016 revealed the onset of THC effects in 15 to 20 minutes, while test subjects praised the taste of the product. The company also entered into a collaborative research agreement with Canada’s National Research Council, which was signed in February 2017. For more information, visit the company’s website at www.LexariaEnergy.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/13/2017 05:22:19 PM
747 LottoGopher Holdings, Inc. (OTCQB: LTTGF) (CSE: LOTO) (FRA: 2LG) Names William Shatner Company Spokesperson - The holding company, through its subsidiaries, operates in California and permits players to buy, manage their Lotto tickets online, and receive exclusive special lottery news - Eyeing expansion in the U.S., LTTGF has hired legal contractor to begin due diligence process for launch into other states - James Morel, president and CEO, said online site has been redesigned, marketing campaigns readied, as company now operates in the $6.3 billion lottery market in California LottoGopher Holdings, Inc. (OTCQB: LTTGF) (CSE: LOTO) (FRA: 2LG) has named William Shatner as its spokesperson, the company announced (http://nnw.fm/2fEu9). One of the world’s best-known actors, in addition to being a director, author, and singer, Shatner is a pop icon figure and Canadian-born personality. Shatner has starred in Star Trek, Boston Legal, and T.J. Hooker, and he has appeared in numerous other TV shows, movies, and plays. LTTGF, based in Vancouver, British Columbia, operates in California as a lottery messenger service that permits users to not only buy state lottery tickets, but also manage them, using debit or credit cards online. LTTGF users can play alone with a single ticket or join online public or private groups to pool winnings from lotteries, including Powerball, Mega Millions and Super Lotto Plus. LTTGF also enables Californians to keep track of their winnings while participating in multiple lottery contests with multiple tickets. It gives members exclusive lottery news, jackpot alerts and lucky number pickers. “I am very happy to be joining the LottoGopher team,” Shatner stated in a news release. “Much like Netflix disrupted the movie rental business and Uber hailing a cab, LottoGopher is disrupting the lottery industry for Americans.” He noted that LTTGF enables consumers to buy lottery tickets online in a cost-effective manner and that he looks forward to helping their customers dream big. In 1997, Shatner teamed with discount travel site Priceline (NASDAQ: PCLN). The Nasdaq-listed stock had an IPO price of $16 per share before skyrocketing to $1,868. Today, the company has a market cap of $99 billion. In a recent news release, James Morel, president and CEO of LTTGF, said, “We are beyond thrilled that William Shatner has agreed to collaborate with us to accelerate awareness of the brand as our spokesperson.” A humorous digital marketing campaign is also being readied. He added that Shatner would open up a “huge audience base” for LTTGF’s online messenger service. “He is one of the most recognizable celebrities in the world.” For a direct link to the William Shatner video, go to http://nnw.fm/X1U2t For more information, visit the company’s website at www.LottoGopher.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/13/2017 05:18:54 PM
746 ProBility Media Corp. (PBYA) Consolidating Skilled Trades Industries eLearning and Training Resources - Offering superior online training for small/medium-sized businesses, previously accessible to only larger companies - Recent acquisitions and joint ventures have expanded ProBility’s offerings to include more products and cover more industries than ever before - Company now includes Brown Technical Media Corp., Brown Technical Publications Inc., Brown Book Shop, Inc., National Electrical Wholesale Providers, W Marketing, One Exam Prep, LLC, ProBility Safety Academy, ProBility Immersive Technologies, Cranbury International and its partnership with GlobalSim Inc. ProBility Media Corp (OTCQB: PBYA) has been driven to serve as many customers in diverse fields as possible, and a solid acquisition and growth strategy has helped it become an emerging leader in the eLearning and training segment. It is developing a full-service training and career advancement brand that is benefiting small- and medium-sized companies that can now have access to the same resources as their larger counterparts. Its product offerings include high-tech training that incorporates intensive interactive media such as virtual reality and 3D modeling. Thanks to ProBility, clients can find these products and more without having to resort to gathering them from multiple sources, saving time, effort and money. Having recently acquired National Electrical Wholesale Providers and W Marketing, Inc., ProBility now serves the electrical industry. A variety of educational courses and exam preparation products are accessible through the company’s website. Any electrical contractor can obtain the training they need and learn how to properly install, maintain, and repair power, lighting, and communication systems. There is also a digital media library of intellectual property animations, plus subscription services that energy/industrial employers can take advantage of. The EdTech company has expanded its scope as much as its industry reach. With the purchase of Cranbury International, it can now offer the same breadth of service to the Caribbean, Central America, and South America. It also now offers heating ventilation and air conditioning training via Brown Technical, plus training materials on ASTM codes and standards, and plumbing and pipefitting training courses, handbooks, and other materials. Its 1 Exam Prep division enables ProBility to offer access to exam preparation at the state, county, or OSHA level. Many of these are business- and industry-specific, allowing those preparing for such examinations to perfect their test-taking skills ahead of time. There are also numerous resources for employers that want to manage their training on-premises. An expanding set of training, compliance and career advancement materials are open to businesses in over 60 trades. Electrical, HVAC, plumbing, crane operations and boilermakers are just a few of them. The ProBility Safety Academy, a joint venture with Range Guard and Investigations, extends courses and exam-prep materials to law enforcement, private security and criminal justice segments in a more accessible way than ever before. ProBility has rapidly become a source of comprehensive online training and exam preparation in multiple industries. Quick and direct access via the Web means that employers don’t have to look far to provide their workforce with industry-leading training that will boost the career potential of their workers and provide these organizations with well-prepared and informed individuals. For more information, visit the company’s website at www.ProBilityMedia.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/13/2017 05:14:26 PM
745 Biosynthesis Technology Could Transform Cannabinoid Production NetworkNewsWire Editorial Coverage: The upward trajectory of the cannabis industry has garnered comparisons to the Internet boom of the early 2000s, as North American sales are on pace to record a compound annual growth rate of 25 percent through 2021, according to Arcview Market Research (1). These comparisons are certainly attention-grabbing, but the full potential of the evolving marijuana market could be even larger. InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), a Vancouver-based biopharmaceutical company, has developed a robust, high-yield biosynthesis process capable of enabling the manufacture of all 90+ naturally-occurring cannabinoids found in the cannabis plant. This could be a game changing development for companies operating within the burgeoning sector, including Axim Biotechnologies, Inc. (OTCQB: AXIM), GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) and pharmaceutical heavyweight Eli Lilly and Company (NYSE: LLY). Perhaps the clearest way to demonstrate the potential of an effective cannabinoid biosynthesis platform is to study a more established product – bio-synthetic insulin. Healthline estimates that 29.1 million people in the United States have diabetes, with diagnosed cases costing the country an estimated $245 billion in 2012. Although the chronic disease accounted for nearly 1.6 million deaths in 2015, according to data from the World Health Organization, a scientific breakthrough in 1921 greatly improved the survivability of diabetes. As documented by a contributor to The Seed Investor, it was then that a team of Canadian researchers discovered a way to process pig pancreases into a human insulin replacement. While this discovery certainly improved the outlook for diabetes sufferers, it was just the first step toward the insulin market as it exists today. Originally, pharmaceutical insulin was produced directly from the organs of pigs, with it taking roughly “5,000 pig pancreases to produce just eight ounces of insulin.” Put simply, this process was expensive and time-consuming, and, while producer Eli Lilly and Company certainly capitalized on the breakthrough, a discovery in the 1970s once again changed the game. A small biotechnology firm called Genentech used recombinant DNA techniques to successfully produce a bio-synthetic “human” insulin, making it the first human protein to be manufactured through biotechnology. In addition to being significantly cheaper to produce than animal-derived alternatives, this synthetic insulin was shown to cause less allergic reactions in patients. Within a few years, biosynthetic insulin replaced the vast majority of animal-based alternatives, and the companies at the heart of the innovation have reaped the rewards. Genentech was acquired by Roche Holdings for $48 billion in 2009, while a 2014 report from Transparency Market Research predicted that the global insulin market will reach $32.24 billion by 2019. Parallels between the insulin market of the 1960s and today’s pharmaceutical cannabinoid industry are too clear to be ignored. Cannabis biotech companies are currently producing millions of plants each year in order to extract the cannabinoids that are central to their products and development candidates. However, maintaining the controlled conditions required to produce consistent plants is both costly and time-consuming, and competitive market conditions in drug development cost will see these pressures from growing and manufacturing expenses. Agricultural and Capital Expense cost are high, from Land, facility costs with high-efficiency lighting systems and sophisticated greenhouse production facilities, investors are pouring millions of dollars into pot production. The cost for the cannabinoids, the active pharmaceutical ingredients (API’s) needed in cannabis drug development are staggeringly high. InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), with its innovative biosynthesis technology utilizing modified E-coli bacteria, could be approaching the introduction of a cheaper and better alternative for providing the API’s in the massive industry’s cannabinoid-focused segment following its filing of a provisional patent application pertaining to the technology earlier this week. Potential benefits of biosynthesis of cannabinoids are wide-ranging, as InMed Pharmaceuticals notes in its corporate presentation. The cost savings versus traditional growing and extraction methods are certainly noteworthy (and they echo the benefits of bio-synthetic insulin nicely), but monetary benefits are just the tip of the iceberg. Because the cannabinoids produced using InMed’s proprietary manufacturing techniques are bioequivalent to the naturally-occurring compounds, biosynthesis could enable enhanced quality control and purification. Importantly, the technology could be key in unlocking the minor cannabinoids that are currently economically unfeasible to produce and comprehensively study. The company estimates that its cannabinoid biosynthesis process, a method that’s been likened to a “pharmaceutical copy machine” for its ability to produce bioequivalent compounds. “This novel approach to the biosynthesis of cannabinoids is a game-changer for drug development. The importance of producing cannabinoids that are identical to the naturally occurring compounds cannot be overstated. Many drug development efforts with synthetic derivatives have failed,” Dr. Vikramaditya Yadav, Assistant Professor of Chemical and Biological Engineering at University of British Columbia, a co-inventor of the biosynthesis technology, stated in a recent news release (http://nnw.fm/Z30dH). “In our extensive experimentation, the E. coli system is more robust and more efficient for the manufacturing of cannabinoids as compared to other microbial platforms.” Links between Eli Lilly’s early ventures in the synthetic insulin market and InMed’s current forays into cannabinoid biosynthesis were reaffirmed by InMed’s January 2017 appointment of Martin Bott to its board of directors. Following Bott’s appointment, market analysis firm CFN Media called the move “a strong vote of confidence for [InMed’s] future.” Bott has worked at Eli Lilly for nearly 30 years prior to his appointment to the InMed board, overseeing the drug giant’s investment of more than $1 billion into biosynthesis research. As InMed President and CEO Eric A. Adams noted in a news release following the addition, “Martin Bott has established a significant leadership position in financial and business expertise with one of the world’s leading pharmaceutical companies. His depth of knowledge in navigating the complexities in healthcare finance and operations on a global level will be invaluable to InMed.” InMed’s intellectual property portfolio also includes a promising drug development pipeline targeting unmet medical conditions using non-THC cannabinoids. The company’s lead candidate, INM-750, is currently being evaluated as a topical treatment for epidermolysis bullosa, an orphan pediatric disease, characterized by extremely fragile skin, that has no currently approved therapies. InMed estimates the market potential of INM-750 at $1 billion, with phase I clinical trials scheduled to begin in 2018. The company is also developing INM-085 for the treatment of glaucoma, a serious eye disease with a global market valued in excess of $5 billion. INM-085 is currently being evaluated in pre-clinical studies. These drug candidates further strengthen InMed’s position within the burgeoning cannabis sector, providing an additional application for its groundbreaking biosynthesis platform. The activity of other cannabis industry players highlights the huge market potential of InMed’s novel approach to cannabinoid biosynthesis. Axim Biotechnologies, Inc. (AXIM) is currently developing a diversified and robust clinical pipeline of cannabinoid-based products. Its most advanced program is its phase II clinical trial of its MedChewRx™ chewing gum for the treatment of irritable bowel syndrome. Axim anticipates completing this trial in the near-term and advancing toward a pivotal phase III clinical trial by early next year. Coinciding with this advancement, Axim has made numerous moves in recent months to secure the needed supply of cannabinoids required to evaluate the efficacy of its development pipeline. In addition to importing pharmaceutical-grade hemp oil from Italy, Spain and Denmark, Axim recently purchased land in the Netherlands in order to facilitate the construction of a state-of-the-art manufacturing facility. Per the company’s website, “Axim is in the process of developing a unique extraction and freeze-drying technology for production of molecularly/genetically controlled—therefore extremely pure—pharma-grade cannabinoids extracted from industrial hemp.” As noted in a November 2016 news release, this platform will focus primarily on the extraction of THC, the most commonly known cannabinoid derived from the cannabis plant. GW Pharmaceuticals (GWPH) is well-known within the cannabis industry as the company behind the world’s first prescription drug derived from the cannabis plant, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries worldwide. The company’s lead cannabinoid product candidate is Epidiolex®, a liquid formulation of pure plant-derived cannabidiol being developed for the treatment of a number of rare childhood-onset epilepsy disorders. As noted on its website, GW is currently in a “unique position to develop and manufacture plant-derived cannabinoid formulations worldwide at sufficient quality, uniformity and scale,” but some analysts have expressed doubt regarding the sustainability of this model. In an article published last year by Seeking Alpha, a contributor noted the recent fall in CBD prices concurrent with increasing supply. “The popularity and history of cannabis growing, combined with the large amounts of arable land, cheap pharmaceutical manufacturing, and cheap labor in India should scare anyone invested in hemp farming,” the article states. “The price-points we are seeing now don’t seem sustainable.” Synthetic cannabinoids, as produced through InMed’s proprietary biosynthesis platform, could provide a long-term solution to this issue. The recent activity of Zynerba Pharmaceuticals, Inc. (ZYNE) reiterates the potential marketability of InMed’s platform. Zynerba’s shares plummeted to 52-week lows last month after the company announced disappointing top-line results from its phase II study of ZYN002, marketed as the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. As noted on its website, Zynerba’s product candidates are “synthetically manufactured per FDA/CGMP regulations” in an effort to “provide consistent potency and eliminate impurities in the product.” Similar to InMed’s biosynthesis platform, Zynerba’s manufacturing techniques offer several advantages over botanically-derived cannabinoids, dodging “the natural resources and security measures required to grow Cannabis, as well as the strict batch controls required by regulatory agencies in pharmaceutical manufacturing.” A report published by the National Institutes of Health affirms that cannabinoids have a very high therapeutic index with low toxicity, and the market is currently filled with companies looking to translate these benefits into returns for shareholders. Since the 1980s, when Eli Lilly and Company (LLY) developed a synthetic THC product called Nabilone to treat nausea associated with chemotherapy, demand for biosynthetically-produced cannabinoids that are bioequivalent to those that occur naturally within the cannabis plant has been on the rise. InMed Pharmaceuticals could be approaching this breakthrough with its robust, high-yield biosynthesis process, presenting an enticing opportunity for investors looking to capitalize on rising demand for cannabinoid-based pharmaceuticals. Editorial Sources: 1) Arcview Research http://nnw.fm/OHz8c For more information on InMed Pharmaceuticals, Inc. please visit: InMed Pharmaceuticals Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/13/2017 05:09:46 PM
744 Cannabis Sector Strategies Light the Way for Industry Growth NetworkNewsWire Editorial Coverage: A new report out from Hexa Research projects that the domestic market for medical marijuana is slated to grow over 250 percent by 2024 to reach a new worth of nearly $20 billion (1). Globally, the market is estimated as reaching some $55.8 billion by 2025. Players in the space are banking on this incredible growth, executing their individual strategies to take part in the vast opportunities. SinglePoint, Inc. (SING) (SING Profile) employs a diversified acquisition-based strategy and is moving toward select joint-ventures to further enhance revenue growth potential as an increasingly cannabis-focused holding company. The goal of any company is growing value, and whether we are talking about up and coming growers like Supreme Pharmaceuticals, Inc. (SPRWF), cannabinoid medicine developers such as Emerald Health Therapeutics, Inc. (EMH:CA), suppliers of proprietary cultivation systems like Surna, Inc. (SRNA), or a holding company like General Cannabis Corp. (CANN), revenue growth and expansion are common objectives. Analysis of publicly available 2016 data by Marijuana Business Daily offers investors clear insight into why companies are looking to gobble up broader footings in this market. One key data point shows that over 64 percent of medical marijuana patients were qualified under chronic or severe pain conditions. Pharmaceutical pain management is a $32.3 billion market in and of itself and is slated to grow at an 8.1 percent CAGR through 2022. Given increased attention to the opioid epidemic in the U.S. and a resounding chorus of voices citing intriguing data such as the 23 percent decrease in hospitalization rates for opioid abuse in states that legalized medical marijuana, we can see clearly why companies want to get their hands on as much of this industry as they can (and fast). It’s no wonder established sector operators (and even new entrants), many of whom are locked into a single revenue-generating vector, are thinking about intelligently branching out the way SinglePoint, Inc. (SING) has over the past year. The real appeal of such a diversified acquisition strategy has the potential to not only accelerate revenue growth by establishing a more robust set of revenue streams, but to gain a more dominant and solid overall footing within the industry. Why just be an isolated cultivator, equipment supplier, or cannabis medicines developer when one can put together a series of proven, profitable entities of this type and become a real powerhouse operation in this seemingly unstoppable and rapidly growing industry? Take a look at how SinglePoint has evolved so quickly, going from a core emphasis on advanced payment technologies and full-service mobile technologies leveraging the company’s SingleSeed subsidiary, to a full-fledged holding company specializing in acquiring small to mid-sized companies, and thus judiciously layering up profitable, parallel interests in the ultra-hot cannabis business. Ever since the acquisition of a strategic stake in revolutionary vape pen filling/sealing system developer and B2C purveyor Jacksam Corp. (dba Convectium) in March (http://nnw.fm/3YFg6), SinglePoint has been on a real tear. Two months later, SinglePoint snapped up 90 percent of California-based cultivation hardware supplier and cannabis consulting outfit Discount Indoor Garden Supply (“DIGS”) Hydro (http://nnw.fm/oh7ZW), and more recently acquired a 51 percent stake in Arizona-based medical marijuana distribution outfit Dr. FeelGood (http://nnw.fm/5rT6R). SinglePoint CEO Greg Lambrecht, noted in a recent interview on MoneyTV with Donald Baillargeon how sage use of its public vehicle has allowed the company to rapidly piece together a much more stable footing in the cannabis industry that already delivered a substantial increase in revenues. The acquisition of DIGS Hydro and Convectium, according to Lambrecht, has increased revenues a whopping 378 times compared to Q1 2017. For a well-positioned operation like SinglePoint, this is music to investors’ ears and Lambrecht also recently pointed out that the company is looking to do more select joint-ventures as well, in addition to further acquisitions that will bring in yet more revenue streams. Looking at Convectium’s revolutionary 710Shark (produced under the BlackoutX brand), which can fill and pack over 100 cartridges for vape pens in 30 seconds at around half the price per machine of the industry standard, it’s easy to understand how Convectium is able to project a 150 percent increase in sales this year to some $3.5 million. This easy-to-use beauty is the only known machine on the market today that can fill cartridges or disposables on this scale for wholesale distribution and the machine utilizes a state-of-the-art dual-heat injection technology that can fill many different types of disposables, using even the thickest of oils. The 710Shark even comes with a 1 horsepower California Air Tools 5.5 gallon, ultra-quiet, oil-free air compressor. The 710 Seal Machine is the other end of the BlackoutX “Fill Seal Sell” System and collectively represents the first such end-to-end system on the market, allowing for easy production of childproof blister packs from loaded cartridges/disposables. Convectium also provides a suite of B2C offerings, which SinglePoint will offer through the SingleSeed platform. DIGS Hydro is already quite well established in retail via an extensive online catalog featuring a wide variety of growing supplies, as well as equipment ranging from HVAC to complete surveillance systems that are tailored to secure a particular grow op. Furthermore, the company provides a number of mission-critical design, construction and maintenance services, covering indoor, greenhouse, and aquaponic setups. This acquisition also grants SinglePoint access to some talented new personnel, such as DIGS Hydro’s top man Carey Haas, who has over 25 years in the industry and will be instrumental to SinglePoint’s decision-making process moving forward on the cannabis side of the business. Recent estimates for the California cannabis market are very promising, with New Frontier’s analysis recently noted in the LA Times projecting 12 percent CAGR over the next eight years to $6.6 billion. This could make the DIGS Hydro acquisition a big feather in SinglePoint’s cap, particularly as the rest of its diversified acquisition strategy plays out. Dr. FeelGood already has an established presence on the widely used cannabis locator site Weedmaps, with a 4.9 out of 5 star rating, and a recent announcement indicates that the company is set to release an app to compete directly with the likes of Weedmaps in just three months’ time. This proprietary mobile application will not only enhance the user experience, it will enable licensing of the technology to other distribution entities in the U.S. once the app is complete. The new app will add substantial weight to Dr. FeelGood’s overall presence, which also consists of a wide variety of B2B and B2C distributed products. By leveraging SinglePoint’s existing location-based delivery technology, the app, which has been on the drawing board at Dr. FeelGood for some time now, will take full advantage of additional features like a directory and ordering system. In this way, the app will offer consumers a souped-up and feature-rich version of already successful, similar offerings in the space. This diversified approach by SinglePoint to the cannabis sector is something for investors to take note of in comparison with other operators in the space today, especially considering how investor-accessible SING’s share price currently is at less than a dime per share. As the pot market continues to mature, we will most likely see an increased drive towards diversification by established sector operators and new entrants alike, with other companies seeking to emulate the roll-up strategy of companies like SinglePoint. This rising trend was mapped out nicely by a recent article in Marijuana Business Daily, highlighting the substantial uptick of M&A activity in the sector. In particular, the Viridian “Deal Tracker” data shows 126 such deals were executed from January 2016 to March 2017 (most likely a conservative estimate). Supreme Pharmaceuticals, Inc. (SPRWF) has pulled back a bit to around $1.02 from highs of early 2017 when it was $1.41 and charging strong, coming off of a banner 2016 that saw completion of the company’s first sale of cannabis genetics to another Canadian Licensed Producer, as well as some $70 million in private placements. This was all subsequent to reception of ACMPR (Access to Cannabis for Medical Purposes Regulations) permission to sell product by the company’s wholly-owned 7ACRES subsidiary in June this year and an uplisting from CSE to the TSX.V exchange. Supreme is quickly realizing its stated mission of producing consistently high-quality cannabis in large quantities for the commercial market and even with a 342,000-square-foot production space at the company’s hybrid greenhouse facility, many investors have not heard the last of this up-and-coming cultivator when it comes to sales. Surna, Inc. (SRNA) recently initiated a comprehensive new branding strategy, including the launch of a new website, in an effort in to draw greater attention to the company’s emergence as a go-to solutions provider for many in the cultivation industry’ particularly for grow ops looking to optimize energy, water usage, and ultimately crop yields. Surna prides itself on providing cutting-edge industrial technology and products for commercial indoor cannabis cultivators. The company’s user-friendly new site is tailored to Surna’s key demographics, such as engineers and contractors tasked with configuring indoor grow ops in the U.S. and Canada, and it is set up in such a way as to facilitate partnering opportunities with those key demos. The company notes that demand for its systems comes primarily from the construction of new cultivation facilities in North America, and said it anticipates more revenue opportunities as more cultivation facilities become licensed amid regulatory changes. Surna reported $1.742 million in second-quarter revenues, and recently landed $1.3 million contract that is currently in the engineering phase. Emerald Health Therapeutics, Inc. (EMH:CA) is a serious contender in cannabinoid formulations for medicinal and/or recreational use. Emerald Health has one of the top batches of cannabis genetics in the sector today under the company’s thumb, as well as advanced R&D and extraction technology at its disposal. The last of which is a key point to take note of, given that cannabis oils have seen exceptional increases in demand, with Health Canada data alone showing an 871 percent increase in the amount sold to Canadian clients from Q4 2016 to Q4 2017 (Jan 1 – March 31). Emerald Health Therapeutics announced back in June that the company is laser-focused on heading towards pharmaceutical formulations and clinical studies, having established an Advisory Board containing several highly reputable doctors and professors, who will provide the much-needed strategic guidance for this process. General Cannabis Corp. (CANN) is a bit more like SinglePoint in its approach to the sector and is designed as a synergistic holding company that provides a one-stop-shop for finding the best cannabis industry service providers. With competencies spanning real estate, consulting, security, financing and infrastructure product distribution, General Cannabis is well on its way to becoming an industry institution. Furthermore, General Cannabis has organized its architecture of subsidiaries to take full advantage of symbiotic relationships between them. Next Big Crop, which represents the company’s operations segment, offers highly professional consulting on cultivation, processing and sales of cannabis via a full-cycle platform replete with hands-on experience rendered techniques. Iron Protection Group is CANN’s security subsidiary and has had its capabilities prominently featured in The New York Times; capabilities only further enhanced by the recent acquisition of Mile High Protection Services as the company seeks to expand an already sizeable position in Colorado’s thriving cannabis market. Chiefton Supply Co. is the apparel wing of the operation and, together with CANN’s brand development and design subsidiary, Chiefton Design, provides a rich and compelling marketing presence for the company. Q2 results for CANN showed revenue up 19 percent year over year, driven in large part by the success of the Next Big Crop subsidiary, which posted a 403 percent increase in revenues over the aforementioned period. The broader cannabis industry is budding with potential, and the lineup of innovators in this global market provides investors a diverse array of investment opportunities. For SinglePoint, a diversified acquisition strategy puts the company a unique position to explore and acquire various targets that keep the company among the leading cannabis plays as it continues to grow its valuation. Editorial Sources 1) Hexa Research: http://nnw.fm/aH2Ri 2) Grand View Research http://nnw.fm/PiO4d For more information on SinglePoint please visit: Singlepoint (SING) or www.SinglePoint.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/13/2017 04:44:08 PM
743 NetworkNewsBreaks – ProBility Media’s (PBYA) One Exam Prep Division Strengthens National Presence with Asset Purchase Agreement EdTech innovator ProBility Media Corp. (OTCQB: PBYA), through its One Exam Prep division, today announced its entry into an asset purchase agreement with Contractor Exam Preps of Pittsboro, North Carolina. Per the company’s news release, this transaction is expected to immediately expand One Exam Prep’s position as a nationwide leader in exam prep for contractors and related licenses, including all NASCLA-related certifications. “One Exam Prep founder and President Rob Estell is a master instructor that has built the division into a powerhouse, from the ground up, and has taken the Company under ProBility to new levels,” Noah Davis, president and chief operating officer of ProBility, stated in the news release. “With sales on pace to exceed a 70% increase year-over-year, combined with the anticipated addition of Contractor Exam Preps, One Exam Prep is poised to enter new markets and offer more to its current and new customers than ever before.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/12/2017 05:28:17 PM
742 NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Records 76% YOY Increase in Revenues for FY2017 Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its financial results for the fiscal year ended May 31, 2017. Among the highlights, the company recorded a 76 percent increase in total operating revenues as compared to 2016. CIIX noted that both its investor relations business and its subscription business posted strong growth during the 12-month period, with revenues increasing by 130 percent and 57 percent, respectively. The company also provided an update on its outlook for fiscal year 2018. “Although the business of our Consumer Division is still in the early stages, the recently launched ‘OptHemp’ product line is gaining popularity among Chinese consumers in the US, and the Company’s first hemp-infused skin care product line will launch in China in the coming months,” Warren Wang, founder and CEO of CIIX, stated in the news release. “We believe that through the efforts of our business strategists … we will generate substantial revenues in FY 2018 via sales of our hemp-based products in the United States and China. Our overall goal in 2018 is for the Company is to achieve annual revenue growth of more than 100%, while cutting costs and achieving profitability.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/12/2017 05:25:12 PM
741 NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Files Provisional Patent Covering Proprietary Biosynthesis Program Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its filing of a provisional patent application pertaining to the company’s biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature. Per the news release, this patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions around the world, will offer significant commercial protections for InMed’s promising E. coli-based expression system, which enables the manufacture of any of the 90+ cannabinoid compounds found in the cannabis plant. “This novel approach to the biosynthesis of cannabinoids is a game-changer for drug development,” Dr. Vikramaditya Yadav, Assistant Professor of Chemical and Biological Engineering at the University of British Columbia, stated in the news release. “The importance of producing cannabinoids that are identical to the naturally occurring compounds cannot be overstated. Many drug development efforts with synthetic derivatives have failed.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/12/2017 05:21:59 PM
740 NetworkNewsBreaks – LottoGopher Holdings Inc. (OTCQB: LTTGF) (CSE: LOTO) (FRA: 2LG) Names William Shatner its Official Company Spokesman LottoGopher Holdings Inc. (OTCQB: LTTGF) (CSE: LOTO) (FRA: 2LG), a provider of lottery ticket management solutions for consumers, this morning announced that actor, director, author and singer William Shatner has partnered with the company to become its new spokesman. Shatner is one of the most recognizable celebrities on the planet, known primarily for his memorable roles on shows like Star Trek, Boston Legal and T.J. Hooker. “I am very happy to be joining the LottoGopher team. Much like Netflix disrupted the movie rental business and Uber hailing a cab, LottoGopher is disrupting the lottery industry for Americans,” Shatner stated in the news release. “Consumers nowadays demand exceptional service, competitive pricing, and the convenience of buying products online. LottoGopher offers a simple, cost-effective way to order lottery tickets online and I look forward to helping their customers dream big!” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/12/2017 05:18:57 PM
739 Algae Dynamics Corp. (ADYNF) Collaborating with Prominent Neuroscientist to Research Benefits of Cannabis Oil for Mental Health Disorders - Partnership between Algae Dynamics and Dr. Steven Laviolette focuses on medical benefits of cannabis and hemp oils for various mental health disorders - Canada is moving to legalize cannabis throughout the country in 2018, which could radically change research playing field - Canadian cannabis oil extraction market projected to reach $1.5 billion by 2020 Algae Dynamics Corp. (OTCQB: ADYNF), a Canadian company focused on the development of proprietary research and products derived from cannabis and hemp oils, has begun a collaborative relationship with one neuroscientist who is looking deep within the brain for answers to some of the world’s most pressing mental health problems. This research agreement with Dr. Laviolette, a neuroscientist at the University of Western Ontario, Canada, is no small thing. The level of human misery and the resulting global economic burden caused by neurological and mental health disorders is hard to fathom. The World Health Organization reports that failure to adequately address and provide effective treatment for depression and other anxiety disorders could cost the world $1 trillion each year, according to research published in The Lancet (http://nnw.fm/3kSsX). “I started working with Algae Dynamics in the spring of this year and it’s going really well, we’re already making quite a bit of progress,” Dr. Laviolette said. “They’re very open-minded and they appreciate the science. They understand the best products come from the best quality science, so I’m very excited to be working with them.” Algae Dynamics approached Dr. Laviolette, because he was already examining how cannabinoids can treat disorders such as addiction, schizophrenia, depression and post-traumatic stress disorder. “We’ve been looking at how we can more effectively utilize different chemicals that are found in marijuana to serve as more effective treatments for some of these devastating illnesses,” Dr. Laviolette says. “Algae Dynamics was taking a holistic approach to this research by not only looking at the specific cannabinoids in marijuana, but they also have a background in the extraction of various nutritional dietary products such as Omega-3 fatty acids. That was very exciting for me.” Emerging research shows that Omega-3 fatty acids can have very strong interactions with the brain’s natural or biological endocannabinoid system and can also modulate the effects of cannabinoids on the brain. If there is a dietary deficiency of Omega-3 fatty acids, the brain’s natural cannabinoid system is not going to work with optimal efficiency, Dr. Laviolette explained. “By contrast, if you can supplement with Omega-3 fatty acids you see certain improvements in the brain’s cannabinoid system, so that immediately got us interested in how synergies between Omega-3 fatty acids and cannabinoids that are derived from marijuana might serve as potential, novel pharmaceutical and nutraceutical products for treating certain specific mental health disorders.” The brain’s natural cannabinoid system is involved in a lot of different processes that relate to mental health, including mood regulation, one’s ability to learn and remember, and certain cognitive tasks. “We know in certain mental health disorders like depression, addiction and schizophrenia, there’s a lot of disturbance in this cannabinoid system,” Dr. Laviolette continued. “So oftentimes people will sort of self-medicate with marijuana and perhaps expose themselves to some of the more negative aspects of it. One compound, in particular, called THC (tetrahydrocannabinol), can have negative effects, especially in younger adults, especially adolescents.” Dr. Laviolette and his team have been comparing and contrasting THC versus other cannabinoids found in marijuana and seek to answer the question of: “What are some of the molecular pathways that they activate and how can we modulate different phytocannabinoids in their formulations and combine them with Omega-3’s to make them less likely to produce some of the negative side effects possible with marijuana exposure?” “We’re looking at both the positive and negative effects, with the goal of really reducing or eliminating the negative effects and really sort of amplifying the positive chemicals that are found in marijuana in terms of treating some of these illnesses,” Dr. Laviolette said. One of the biggest concerns of the medical community, and one reason a lot of doctors are not very willing to prescribe their patients cannabinoids in terms of treating mental health symptoms like PTSD, depression or even schizophrenia, relates to the potential negative side effects, he added. “What we’re really trying to do is tease apart the positive and negative aspects of marijuana. We’ve been able to show CBD can actually be a promising treatment for a variety of mental health disorders like PTSD and schizophrenia,” Dr. Laviolette said. “It’s quite amazing because, when you think about it, it’s the same plant but these two different, competing chemicals are producing different effects in terms of mental health.” Another major issue associated with using cannabinoids as a medical treatment is that people “aren’t really too keen on the idea of just smoking cannabinoids,” he said. “So, one of the major research directions we’re taking with Algae Dynamics is coming up with more effective non-smoked formats of medical marijuana, which includes oil-based formulations.” Algae Dynamics’s focus on supporting research directed at the medical benefits of cannabis and hemp oils is providing a critical lifeline to scientists like Dr. Laviolette. “The other aspect is that it’s very difficult to do this research because of all the different government regulations that you need to go through to, first; get ahold of the actual compounds, and second; get the actual license to perform these sorts of studies,” he said. Canada is heading toward legalization of cannabis throughout the country in 2018, which could bode well for the research community, investors and companies like Algae Dynamics. “People are excited. I think there’s a general feeling that cannabinoids are absolutely going to be an emerging biotechnology in the coming decades,” said Dr. Laviolette. “Companies like Algae Dynamics are actually taking this research seriously and are getting in on the ground floor of the development of effective cannabinoid products.” While solid, quality research takes time, Dr. Laviolette said his team is now moving toward the clinical realm with the goal of collaborating with clinicians sometime within the next few months. Discovering the ideal ratios of THC and CBD and then combining those with a nutritional supplement such as Omega-3 fatty acids is expected to lead to the best formulations for an early stage clinical trial. “I think there’s tremendous potential for development of pharmaceuticals and nutraceuticals based on that,” Dr. Laviolette says. “I’ve been doing this research for well over two decades now and what you consistently realize is that the existing drugs available for treating some of these symptoms have some really bad side effects. So, it’s not only the limited effectiveness of a lot of these drugs used to treat depression and anxiety, but the serious side effects that make a lot of people stop taking them. It’s essentially a barrier of sorts to long term treatment.” Dr. Laviolette’s research is providing early, promising evidence that there are very few side effects associated with cannabidiol, or CBD, which is a non-psychoactive compound in marijuana. “I think there’s tremendous potential to develop pharmacological treatments that are derived from natural products that are relatively pure. I think they’ll be a much more promising alternative than the more traditional medications that are out there right now,” he added. Cannabis is a complex plant with well over 100 different phytochemicals, a fact that Dr. Laviolette describes as exciting but also one that means researchers are just barely beginning to “scratch the surface.” For more information about Dr. Laviolette and his research with Algae Dynamics, visit the company’s website at www.AlgaeDynamics.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/12/2017 05:15:46 PM
738 India Globalization Capital, Inc. (NYSE: IGC) Announces Alzheimer’s Drug Candidate Targeting Aβ Proteins - More than 5.3 million people in the U.S. have Alzheimer’s disease, which has no effective cure or substantial treatment - India Globalization Capital’s IGC-ADI drug candidate targets proteins associated with the buildup of lesions in the brain - The company acquired exclusive rights to a patent, based on University of South Florida studies supporting THC’s role in inhibiting Aβ plaque production Alzheimer’s disease now affects over 5.3 million people in the United States, imposing an estimated economic cost of $236 billion. There has been no effective treatment to slow down or reverse its effects. That may be about to change, as India Globalization Capital, Inc. (NYSE MKT: IGC) launched a press release (http://nnw.fm/Dxc49) detailing its work on a drug candidate, IGC-ADI, that targets the buildup of lesions in the brain associated with Alzheimer’s. Given that the number of cases is expected to double over the next two decades, a lack of a cure or other mitigating therapy is concerning. However, the company expects to soon begin trials that may yield promising new treatments. The unconventional nature of this drug candidate is that it is tetrahydrocannabinol (THC)-based. Low doses of THC have been found to inhibit amyloid beta peptide (Aβ plaque) production. This protein is believed to cause plaque to form in the cerebral cortex and hippocampus. Phosphorylated Tau proteins make up another type of lesion, called a neurofibrillary tangle, that is also linked to AD. The Aβ proteins normally cleared away by biological processes are unregulated in Alzheimer’s patients, and therefore build up into insoluble fibroles. The result is the formation of senile plaques and extracellular misfolded oligomers that are thought to be toxic to nerve cells in the brain. Now the only publicly traded pharmaceutical cannabis stock that addresses the disease, IGC has developed a drug that inhibits protein production and protein aggregation and reduces the phosphorylation of protein, as explained in the recent Brand Awareness Distribution article, “Alzheimer’s Disease: Cannabis Formulation Shows Promise”. The drug candidate IGC-ADI is believed to also have the potential to restore mitochondria function and redirect the immune system. Studies on genetically engineered cell lines conducted at the University of South Florida (USF) have provided supportive evidence for the company to move forward. At THC concentrations of 25nM, Aβ40 production was cut by 30 percent over a six-hour period, and by 35 percent over 24 hours. When doses of 2.5 μM were introduced, amyloid beta peptide production was reduced by the same level at six hours, 40 percent over 24 hours, and 55 percent over 48 hours (compared to 40 percent at lower THC concentrations). The patent “THC as a Potential Therapeutic Agent for Alzheimer’s Disease,” was filed based on the findings of the USF studies conducted by Dr. Chuanhai Cao, an Associate Professor of Pharmaceutical Sciences at USF’s College of Pharmacy and an IGC Senior Advisor. Expected to conduct human medical trials, IGC has already acquired exclusive rights to the patent filing, allowing it to use and advance the technology to find potential treatments for Alzheimer’s patients. IGC-ADI is one of six patents involving cannabis-based combination therapy, providing investors with opportunities to help support potentially revolutionary treatments for Alzheimer’s, epilepsy, Parkinson’s disease, depression and post-traumatic stress disorder. For more information, visit the company’s website at www.IGCInc.us Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/12/2017 05:08:14 PM
737 ORHub’s (ORHB) Revolutionary Software Solution Could Help Pave the Way to Value-Based Healthcare in the US - ORHub is a pioneering cloud-based healthcare solution that can help medical providers eliminate inefficiencies, cut costs and improve quality of care - ORHub has created a new category of healthcare IT vertical-specific software called surgical resource management (SRM) - ORHub creates the largest source of intelligent surgical information in the world, opening up a vast pipeline of revenue opportunities - ORHub is positioned to become the universal SRM platform for improving healthcare efficiency and cutting costs “Value-based healthcare” is a buzz phrase these days, and surgical procedures are at the center of the issue, with hospitals spending, on average, between 48 and 50 percent of their revenues on surgery while outdated tracking systems cripplingly hold back progress, making it impossible for medical facilities to cut costs without sacrificing quality of care. One pioneering company, ORHub, Inc. (OTC: ORHB), has been working with Microsoft (http://nnw.fm/W4iTT) to break new ground and bring the United States healthcare system into the digital age—an evolution that is sorely needed in order to improve healthcare practices and lower costs in a country that is infamous for having the highest healthcare costs in the entire world. The key is the ORHub solution, which has created the largest source of intelligent surgical information in the world and provides a suite of products that can better serve the needs of the healthcare industry, patients and the government. ORHub’s cloud-based software solution captures information at the point-of-care, filling a huge void in the surgical information infrastructure by transforming big data into intelligent data. The ORHub solution replaces various antiquated legacy systems with a 360-degree solution that enables the tracking of healthcare costs from diagnosis to discharge, allowing all parties involved in surgical care to collaboratively organize, deliver, measure and reimburse via one intuitive, uniform program. This helps eliminate inefficiencies, duplication of services, and errors and omissions that currently result from siloed software processes and insufficient hand-offs across the care chain. The result will be substantially lowered healthcare costs and drastically improved patient outcomes. The ORHub solution was born in a hospital surgery center, where forward-thinking surgeons and administrators realized they didn’t have the information they needed to reduce costs without negatively impacting quality of care. In the past, healthcare organizations have been blindly making decisions about how to improve their processes and redesign care without having a true understanding of the actual costs of care for a patient’s condition and how those costs relate to outcomes. Rather than working synergistically, clinicians have instead been battling over arbitrary cuts. ORHub’s cloud-based software platform is the solution to these inadequacies and inefficiencies. Through ORHub’s software applications, hospitals and medical device vendors will be able to use any Web-enabled device to generate a detailed anatomical graphic depiction of what happens during surgery. The resulting schematic is then automatically translated into an intelligent electronic operative report that links every detail of a surgery to produce a dynamic new source of comparative data. Through ORHub’s revolutionary solution, hospitals, surgeons and vendors can now make decisions that are real-time and data-driven to improve both profitability and quality of care. Further, costs are resultantly reduced for both hospitals and vendors, accountability is improved, surgical implant registries are automated, real-time advanced analytics are created and compliance is bettered. ORHub is disrupting archaic industry processes, making it possible for tasks that used to require teams of people working by hand to invest weeks or months to now be done directly at the point-of-care by just one person. For the very first time, surgical data can be utilized to create real-time evaluations, self-generate future statistical ratings, and provide predictive outcomes-of-care. ORHub’s innovative cloud-based solution has created a new category of healthcare IT vertical-specific software called surgical resource management (SRM), which is a category that enables enhanced capabilities as well as access to valuable analytics. This SRM platform will create the largest source of intelligent surgical information the world has ever seen, simultaneously opening up a pipeline of revenue opportunities for ORHub. ORHub is positioned to become the universal SRM platform for improving efficiency and mitigating costs. The ORHub story started in 2015, when company CTO Wesley Mitchell was contacted by the Microsoft for Startups Program to help a surgeon who wanted to develop a software program that could help analyze resource allocation for surgical procedures—a project that immediately intrigued Mitchell. Over a period of two months, he and his associates interviewed clinical and administrative professionals in the healthcare field and then applied for BizSpark Plus credit from the Microsoft for Startups Program to develop the ORHub solution. A pilot program was collaboratively developed by the ORHub team and Microsoft at the #5 orthopedic hospital in the nation. The solution was developed on the Microsoft Azure platform, which was already encrypted and built with HIPAA considerations in view. ORHub went from concept to production in under a year. ORHub’s state-of-the-art, disruptive solution has the potential to drastically and lastingly impact the U.S. healthcare system, improving costs, patient outcomes, resource allocation and more. A brighter healthcare future is now within reach thanks to this pioneering technology. For more information, visit the company’s website at www.ORHub.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/12/2017 05:04:41 PM
736 Alzheimer’s Disease: Cannabis Formulation Shows Promise NetworkNewsWire Editorial Coverage: Known as America’s most expensive disease, with an estimated cost to the U.S. economy of $236 billion in 2016, Alzheimer’s disease (AD) affects more than 5.3 million Americans. Over the next 20 years, the number of those afflicted with the disease is expected to double. The forecast is staggering, considering that no effective cure has been found, but the quest for one continues, with India Globalization Capital, Inc. (NYSE: IGC) (IGC Profile), Anavex Life Sciences (NASDAQ: AVXL), Axovant Sciences (NYSE: AXON), AC Immune Ltd. (NASDAQ: ACIU) and Biogen, Inc. (NASDAQ: BIIB) all exploring a variety of approaches to uncover the pathological pathways of this chronic neurodegenerative disease. It is believed that Alzheimer’s disease is caused by two types of legions in the cerebral cortex and hippocampus: senile plaque composed of the protein beta-amyloid (Aβ plaque), and neurofibrillary tangle, composed of highly phosphorylated Tau protein. The surface of neurons has a protein called APP that is sectioned by enzymes to free up the Aβ protein that is then cleared by the body. In Alzheimer’s patients, however, there is an imbalance whereby Aβ protein is not regulated and builds up abnormally into insoluble fibroles, creating senile plaques. Currently, India Globalization Capital (IGC) is the only publicly traded pharmaceutical cannabis stock that addresses Alzheimer’s disease, which positions the company with a first-mover advantage in phytocannabinoid-based combination therapy (http://nnw.fm/0QDQz). The company’s drug candidate, IGC-ADI, works through a molecular pathway that allows low doses of tetrahydrocannabinol (THC) to 1) inhibit Aβ protein production, 2) inhibit Aβ protein aggregation, 3) reduce protein phosphorylation, 4) potentially restore mitochondria function, and 5) potentially redirect the immune system. IGC’s evidence supporting this theory is based on two studies done on tissue and mice at the University of South Florida (USF). The USF study found 1) THC to be effective at lowering Aβ levels in N2a/AβPPswe cells at extremely low concentrations in a dose-dependent manner over a 48-hour period; 2) that THC directly interacts with Aβ protein, thereby inhibiting aggregation; 3) that THC was effective at lowering both total GSK-3β levels and phosphorylated GSK-3β in a dose-dependent manner at low concentrations; and 4) that low doses of THC can increase mitochondria function. These studies led to the filing of a patent by USF entitled, “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” IGC acquired the exclusive right to this patent filing and expects to advance the technology and IGC-AD1 through medical trials. The theory is further supported by a study conducted by researchers at the Salk Institute of Biological Studies, who drew similar conclusions. In June 2016, the Institute, in a news release (http://nnw.fm/E5Ecm) headlined “Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells,” revealed that its scientists had found preliminary evidence “that tetrahydrocannabinol (THC) and other compounds found in marijuana can promote the cellular removal of amyloid beta, a toxic protein associated with Alzheimer’s disease.” A look at other approaches in the market emphasize the unique position occupied by IGC, as well as the exciting potential of ongoing research. Anavex Life Sciences (AVXL), for example, is focused on research aimed at treating more than just the symptoms of Alzheimer’s. The company’s lead candidate, Anavex 2-73, recently completed a phase 2a trial in patients with mild to moderate Alzheimer’s disease, showing a favorable safety and bioavailability profile and dose response curve. Early preclinical studies generated a great deal of excitement, because they indicated that Anavex 2-73 could potentially halt or reverse the course of Alzheimer’s disease through restoration of the body’s homeostasis, according to a report (http://nnw.fm/uN7LN). At Axovant Sciences (AXON), an air of expectation is mounting as the company anxiously awaits the outcome of a phase 3 trial, started in 2015, for its lead Alzheimer’s candidate, intepirdine. Results are expected by the end of September 2017. Axovant’s drug works in conjunction with another Alzheimer’s drug currently in use, donepezil, and acts on the 5HT6 receptor as an antagonist. While donepezil inhibits the loss of acetylcholine, a chemical in the brain that transmits signals, intepirdine appears to increase the production of that vital medium. In August, AC Immune (ACIU) announced the discovery of new antibodies that target biomarkers other than Aβ and tau. A news release (http://nnw.fm/WA9xS) reports that “These next-generation antibodies were discovered using the company’s proprietary SupraAntigen™ platform, which has already generated four products in clinical development, including crenezumab partnered with Genentech/Roche in Phase 3 for Alzheimer’s.” Biogen (BIIB) has also joined the quest for an Alzheimer’s elixir. Its experimental drug to treat the condition, aducanumab, is now in pivotal trials. The company’s valuation soared by more than a billion dollars after analysts at Goldman Sachs (NYSE: GS) added it to their Equity Conviction List, according to the Boston Business Journal (http://nnw.fm/HlL7E). These efforts to defeat Alzheimer’s are fueled by compelling incentives. Some 5.5 million Americans suffer from the malady, which kills more than breast cancer and prostate cancer combined. The market potential of a remedy has been estimated at over $5 billion, putting IGC at a sweet spot in the conjecture of the medicinal applications of THC and disease treatment. For more information on India Globalization Capital, please visit: India Globalization Capital (IGC) or http://www.igcinc.us Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/12/2017 04:55:36 PM
735 Cannabis Biotechs Taking Leading Stance in Global Marijuana Market With leading recent estimates clocking the 2016 North American legal cannabis market between $6.7 and $7.2 billion, the only thing more impressive about the industry is the growth projections. Research estimates a whopping compound annual sales growth rate of 25 percent through 2021. This stupendous growth, driven by more and more states adopting medical and even recreational legislation, has combined with the fact that the FDA has not yet approved any drug product containing or derived from botanical marijuana to create a perfect storm for cannabis biotechs like Vancouver-based InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) and GW Pharmaceuticals (NASDAQ: GWPH). Medical marijuana has among the highest values in the broader marijuana space, and as with any burgeoning industry, savvy investors are looking for evidence of the market’s core value. A look at the operations of Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF), Aphria, Inc. (TSX: APH) (OTC: APHQF) and Aurora Cannabis (TSX: ACB) (OTC: ACBFF) provides insight into various niches within the marijuana industry to help identify why cannabis biotechs are the value sweet spot. Despite its incredible potential, the success of medicinal marijuana’s success in the U.S. is crimped by cultivation capabilities. Due to the notoriously stringent regulatory environment in the U.S., much of the research and even plant cultivation has historically been done outside the country, with Israel rapidly evolving into the premier cannabis research and development location on earth, as the nation’s scientists and producers chase what will potentially be a $50 billion global market by 2025. Second only to Israel in this regard is Canada, where top growers are benefitting from Access to Cannabis for Medical Purposes Regulations (ACMPR) that allow commercially licensed production. This limited participation market has been very good for Canadian growers that have achieved licensing, with only 58 participants to date. However, the real value of the industry lies in the biotechs using cannabinoids extracted from the cannabis plant to develop their drug candidates and potentially change the entire future landscape of the medical marijuana industry. Evidence of the value of cannabis biotechs is revealed in the Bloomberg Intelligence Global Cannabis Competitive Peers Index (http://nnw.fm/8bZ6k), which shows the collective market cap of cannabis bio-pharma at $5.6 billion, outpacing the valuation of cannabis producers at $3.4 billion. While current cannabis drug development is handicapped by the expensive industry standard “grow-harvest-extract-purify” process, GW Pharmaceuticals’ ability to jump from $8 a share to more than $120 a share following news of its new drug, is a prime example of the types of gains cannabis biotechs can achieve, and what makes them dominate the Bloomberg index. As noted in the Bloomberg piece, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) could become a major breakout player, differentiating itself from leading developers like GW Pharmaceuticals with biosynthetic offerings and two key drug indications. This is a key advantage for InMed, which has a market cap of $34 million, but to better understand this advantage and valuation potential, it pays to examine the underlying market dynamics in greater detail. There are more than 90 cannabinoids that have been isolated from cannabis, each affecting the body’s cannabinoid receptors and responsible for unique pharmacological effects. Because these cannabinoids are so small in size, isolating these compounds in usable volume requires the cultivation of large quantities of cannabis, currently some cannabinoid compounds are found in such small volumes in the plant they are not commercially viable for study in drug development. InMed Pharmaceuticals, however, enjoys the unique benefit of developing a cannabinoid biosynthesis process to provide access to the entire suite of all 90 plus naturally-occurring cannabinoids (not just THC or cannabidiol). Rather than having to rely on outside cultivators in Israel or Canada, InMed uses its proprietary, high-yield biosynthesis process capable of manufacturing pharmaceutical grade, bio-identical cannabinoids in the lab. Diseases such as the primary targets of InMed’s current drug development pipeline, like glaucoma, which the company is targeting the root cause of via INM-085. Designed as a topical formulation which facilitates absorption by the eye, the proprietary, polymer-based INM-085 is a novel, multi-target, multi-mechanism package of cannabinoids focused on relieving the intra-ocular pressure build up which leads to optic nerve damage in glaucoma patients. INM-085 simultaneously provides key neuroprotectant properties that help optic nerve tissues and retinal ganglion cells survive adverse conditions. Glaucoma therapeutics was a $5.7 billion market only two years ago, with projections of a 3.4 percent CAGR through 2024, and the broader ophthalmic drug market is on-track to top $30 billion by 2020. Another disease currently targeted by InMed’s development pipeline is epidermolysis bullosa (EB), a connective tissue disorder characterized by the absence of certain proteins in the skin, and currently classed as an orphan disease for which there remains significant unmet medical need. INM-750 is just as novel as INM-085, utilizing a broad-spectrum approach to modulate levels of the key protein responsible for protecting epithelial (skin) cells from damage and stress, known as keratin. In addition, INM-750 was specifically designed to alleviate associated symptoms like inflammation, itching, pain, while promoting wound healing, and skin cell regeneration. INM-750 is on target for clinical trials as early as next year and the global market for EB and glaucoma combined is easily over $6 billion. These target markets are just the tip of the iceberg, in terms of market opportunity. With a valuation of $3.4 billion, GW Pharmaceuticals (NASDAQ: GWPH) may be the frontrunner in the search for cannabis-based therapeutics, but small biotechs like InMed (CSE: IN.c) (OTC: IMLFF) are demonstrating the vast potential of cannabis therapies and their value in the broader medical industry. GW Pharmaceuticals has been in the cannabinoid research game since the late 90s and has become one of the most talked about developers of plant-derived cannabinoid therapeutics today. Widely known for bringing the world’s first plant-derived cannabinoid prescription drug (Sativex) to market for spasticity in multiple sclerosis patients, GW Pharmaceuticals markets the drug in 29 countries outside the U.S. and is currently in phase 3 pivotal trials for Epidolex, which has been granted both Orphan Drug Designation and Fast Track Designation by the FDA. The company also famously decided to keep its entire plant production footprint in the UK last year, despite driving hard toward sizeable U.S. markets with Epidolex, and migrating its shares from London markets exclusively to the Nasdaq exchange. The success and valuation of Canada’s medical marijuana growers, cultivators and producers sheds light on increasing global demand and necessity for high-volume, high-quality plants for medicinal purposes. Canopy Growth’s (TSX: WEED) (OTC: TWMJF) is among leaders on the production side of the marijuana industry, with a market cap of $1.4 billion (CAD) as of September 11. The company’s Bedrocan brand is billed as the epitome of medical-grade cannabis due to decades of selection and refinement. Enabling the company to produce consistent, standardized whole bud cannabis strains, as well as see those strains become used extensively by clinical researchers across seven European countries. With a production footprint of over half a million square feet, Canopy Growth is one of the biggest growers in Canada. The company recently moved to further solidify its expansion in New Brunswick with the acquisition of ACMPR applicant Spot Therapeutics, which when licensed will produce roughly 8,800 pounds a year, and when fully expanded will provide around 100,000 square feet of production space. The company also expanded its Smiths Falls and our Bowmanville South footprints last quarter by 33% and 200% respectively. Currently valued at $831.5 million (CAD), Aphria, Inc. (TSX: APH) (OTC: APHQF) is one of the lowest cost producers in Canada and was the first publicly licensed producer to go cash flow positive from operations. The recent announcement of a $25 million investment in order to effectively gain a strategic U.S. presence via one of only seven licensees in the entire state of Florida is a big move for the company, which will operate in the U.S. under the Aphria USA brand. A big move, but with nearly 21 million people in Florida and many of them elderly, this market could be a real goldmine for Aphria, as it represents some 14 percent of the total U.S. medical cannabis market, valued at over $1.1 billion. Aurora Cannabis, Inc. (TSX: ACB) (OTC: ACBFF) surpassed 19,000 active registered patients in the company’s first 20 months after initial product sales and has over 55,000 square feet in Alberta at its state-of-the-art production facility. Aurora is also currently in the process of tacking on an additional 840,000 square feet across two other sites in Canada. The company owns a 19.9% stake in the first Australian company licensed to cultivate and conduct research on medical cannabis, Cann Group Limited. As well as owning a leading Germany-based wholesale importer, exporter, and distributor of medical cannabis, known as Pedanios. Pedanios even recently passed the first stage of the tender application process in Germany to become a licensed medical cannabis producer, which will further expand the company’s presence in the EU. Aurora’s market cap is $969.0 million (CAD) As investors find their footing in the global marijuana industry, the potential for cannabis biotechs is reaching unprecedented proportions thanks to the innovations and drug development capabilities of companies like InMed and behemoths like GW Pharmaceuticals. For more on IMLFF please visit: InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/12/2017 04:44:44 PM
734 NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Retains Biopsy, LLC to Provide Leadership in Growth and E-Commerce Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its retention of Biopsy, LLC, managed by bestselling author Chris J. Snook, to provide leadership in growth and e-commerce. Effective September 1, 2017, Biopsy, LLC will serve as the architect of the digital infrastructure and go-to-market strategy for ChineseInvestors.com, Inc. and its subsidiaries, reporting directly to the companies’ management teams. “ChineseInvestors.com, Inc. is fortunate to be able to contract with Biopsy, LLC as Chris’ unique skill and experience will enhance the Company’s ability to effectively emerge as a leader in the CBD Biotechnology Industry, while also strengthening and expanding the market reach and value of the Company’s core financial media business,” Warren Wang, CEO and founder of CIIX, stated in the news release. “Online purchases by Chinese consumers now exceed that of US consumers and global online sales are expected to grow 20% annually. ChineseInvestors.com, Inc. is committed to building the necessary platforms to capitalize on this growth trend and to emerge as a market leader.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/11/2017 05:32:30 PM
733 NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Provides Update on Data Linking THC to Decrease in Aβ40 Protein Production India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced compelling in vitro data compiled from genetically engineered cell lines showing that, at varying concentrations of THC, the production of Aβ40 protein decreases by as much as 50 percent over a 48-hour period. This is particularly noteworthy for patients with Alzheimer’s disease, as the condition often results in an imbalance of Aβ plaque that is believed to be toxic to nerve cells. This data, compiled by Dr. Chuanhai Cao, an IGC senior advisor and associate professor of pharmaceutical studies at USF’s College of Pharmacy, led to the filing of a patent by USF entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” In the news release, Ram Mukunda, CEO of IGC, stated, “IGC acquired the exclusive right to this patent filing and we plan to advance this technology through medical trials that can potentially bring much needed relief for patients suffering from AD.” Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/11/2017 05:28:44 PM
732 AppSwarm, Inc. (SWRM) Focuses on Key Revenue Streams to Leverage its Growth Strategy - AppSwarm, Inc. reported $589,000 in revenue for 2016 and has continued to focus on growth in 2017 - The company has focused on four key revenue streams to boost the success of social game development, mobile apps, and e-commerce websites - A proprietary screening process enables it to select app ideas with the most potential, based on their benefits for developers, entrepreneurs, and consumers Earning $589,000 in revenue for 2016 hasn’t given AppSwarm, Inc. (OTC: SWRM) a reason to slow down. From in-house development to assets gained through mergers and acquisitions, the company has focused on a vigorous growth strategy centered on a proprietary business model. This is known internally as the “Swarm”. The publicly traded company has focused on engagement, retention, virality, and monetization to secure its revenue streams and sustain its position in a high-demand market, boost the value of its products, and continue a pattern of growth, all at the same time. The four key revenue streams driving the company’s progress include the incubation of apps, using completion of concept and development, market analysis, sales/marketing, and financial management services. AppSwarm is also highly engaged in social game development. It has developed highly relevant concepts internally, although it has also been successful in purchasing and redeveloping existing games and applications. Focusing on specialty niches has boosted revenue as well, especially casino and role-playing movie-themed applications. Several projects have involved partnerships leveraging technology and market expertise, allowing the company to apply each product to the specific market in an appropriate way. Continual growth has been facilitated by AppSwarm’s unique approach to product development. Its proprietary selective screening process involves a detailed review of each app idea’s benefits. The decision-making process is considered beneficial for developers and entrepreneurs, but this isn’t the only strategy employed. Mergers and acquisitions aren’t unusual in software development, but the company’s expertise and support in business management/development, capital, and other areas contributes to its repeated success in the M&A circuit. E-commerce, health, and education represent just a few of the sectors the company’s M&A strategy has focused on. Its e-commerce development has concentrated on the mobile device market and the anticipated increase in online sales driven by purchasing activity of potentially 270 million people by 2020, according to Forrester Research Inc. AppSwarm’s e-commerce development has delved into the world of virtual reality. It has also contributed to the success of websites such as Urban Bamboo Designs, an online retailer of low carbon footprint products, and Authlinks, an authority links resource serving bloggers and website owners. AppSwarm has also built its revenue by tapping into the $99.6 billion global games market. From soccer to the battlefield to fun family game apps, the company has taken gamers to diverse realms. An optical character recognition-enabled application for scanning PDF documents universally works on all iPhones and iPads. The company’s focus on entertainment, productivity, and web development has enabled it to reach into a large market base, provide useful services for end users, and grow its revenue and position with investors/developers from all walks of life. For more information, visit the company’s website at www.App-Swarm.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/11/2017 05:25:42 PM
731 SinglePoint, Inc. (SING) Acquires Dr. FeelGood; Plans in View for Multistate Brand Expansion - SinglePoint has completed its third acquisition of 2017 - Company’s revenue has grown 378-fold since first quarter 2017 - Delivery application in development will directly compete with Leafly and WeedMaps - Company well-positioned to continue acquisition strategy and further increase revenue Marking its third acquisition of 2017, SinglePoint, Inc. (OTC: SING) announced on September 6 that it has acquired profitable cannabis distribution company Dr. FeelGood. According to the agreement terms, SinglePoint will acquire 51 percent of the company in a combination of cash and stock, allowing SinglePoint to recognize all revenue. This acquisition adds yet another revenue stream for SinglePoint, further affirming the company’s strategy of revenue by acquisition. The acquisition further provides SinglePoint with new team members who have been active within the cannabis industry for many years. Based in Phoenix, Arizona, Dr. FeelGood is a leading medical marijuana distribution company that has expansion plans to add a proprietary delivery and ordering technology application. Dr. FeelGood’s founders have established a development plan to create a proprietary mobile application that will both enhance the experience for users and streamline the company’s operations. The app is scheduled to be released within 90 days. Once the app is completed, both companies will be able to license the technology to other distribution companies throughout the United States. The two companies are also collaborating on a delivery platform, and SinglePoint will leverage its location-based delivery application and add other features, including a directory and ordering system that will compete directly with Leafly and WeedMaps. Dr. FeelGood was already pursuing plans to build the app; with SinglePoint’s progress, the company will be able to utilize the app much earlier than anticipated and begin providing it to interested entities. Dr. FeelGood offers a broad array of products that are distributed through both B2B and B2C. Current owners Scott Riley and Jeff Clevenger will continue overseeing the company’s day-to-day operations, with plans in view to expand the business and license the Dr. FeelGood brand in other states. Other SinglePoint acquisitions that have taken place in 2017 include California-based companies DIGS Hydro and Convectium. With these acquisitions, SinglePoint’s revenue has increased 378-fold in comparison with 2017’s first quarter, ideally positioning the company like never before. SinglePoint is well-capitalized to continue its acquisition strategy and further increase revenues. For more information, visit the company’s website at www.SinglePoint.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/11/2017 05:09:58 PM
730 Sep 11 #OTC #LowPriced #WatchList $AGTK $ARWD $AVEW $AZFL $DOLV $DTII $GEGI $ICNB $LAHO $LIGA $MVES $ONCI $OTTV $QSIM $SRMX $UPZS $VDRM Good Friday, ARWD lead the way on today's #WatchList for a total potential profit +317% (open to today's hod) and +356% (previous close to hod) https://cdn.discordapp.com/attachments/299888908999720960/355807298750382090/image.png three2001 09/08/2017 10:33:36 PM
729 ChineseInvestors.com, Inc. (CIIX) Aiming to Grow Direct-to-Consumer e-Commerce Business - Company engages Launch Haus LLC, a digital agency, to grow its direct-to-consumer e-commerce business through a new marketing campaign - Consilium Global Research (http://nnw.fm/e5EiK) projects a CAGR of nearly 100% for CIIX through FY2020, with revenues reaching $14.8 million - CIIX has goal of becoming the largest Chinese publicly traded company in the legalized cannabidiol (CBD) market, with a target audience of the global Chinese-speaking community ChineseInvestors.com, Inc.’s (OTCQB: CIIX) goal of growing its global sales of hemp-based cannabidiol (CBD) products will be aided by its engagement of Launch Haus LLC, a Scottsdale, Arizona-based holding company specializing in digital direct-to-consumer marketing and product branding. CIIX has a goal of becoming the primary Chinese medical cannabis publicly traded company. It is focused on the research and development and distribution of legalized CBD to the global Chinese-speaking community. It has an online store in the free trade zone of Shanghai, China, and plans to open a brick-and-mortar store in its home market of San Gabriel, California. Sales of CBD are legal in China, while marijuana is not. In a recent update, WallStreetResearch.org (http://nnw.fm/7r0Rp) noted, “Launch Haus has been engaged to develop a customized cutting-edge direct response marketing campaign that will focus on personalized, customer-centric marketing and sales force automation; develop a compensation plan that incentivizes both rapid growth through recruitment of new, entry-level consumers and top-tier distributors; introduce CIIX to its stable of industry-leading suppliers for global payment systems and logistics and its network of distributor recruitment and legal governance and compliance professionals.” The report added that the principals of Launch Haus have a proven track record of building sales organizations and developing go-to-market planning and customer experience consulting. CIIX, it notes, believes it is on track to announce an official launch date of its direct selling platform in the coming fiscal year. Consilium Global Research projects that CIIX will achieve sales of $14.8 million by FY2020, outpacing the growth of the CBD market with a compound annual growth rate (CAGR) of nearly 100% in that time period. For more information, visit the company’s website at www.ChineseInvestors.com Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer networknewswire 09/08/2017 06:05:59 PM
728 Sept 8 #OTC #LowPriced #WatchList: $ABBY $AMMX $APHD $ARWD $DCTH $FUTL $GVCL $HMPQ $IMTL $LQMT $ONCI $PFWI $RMRK $SNMN $TVIAQ $VATE three2001 09/07/2017 09:00:06 PM

  • You agree not to use any obscene or offensive language to place on the discussion forum including any material that is profane, inaccurate, defamatory, false, inappropriate, threatening, hateful, constitutes junk mail or unauthorized advertising, infringes on any person’s privacy, violates copyright laws, encourages conduct that would constitute a criminal offense, give rise to civil liability, or otherwise be in violation of any local, state, national, or international law or regulation. iTalkPennyStocks.com reserves the right to remove any such content at any time without your consent.

  • To maintain relevant content, iTalkPennyStocks.com reserves the right to remove messages we assess to be inappropriate or off topic and conduct editing we identify as reasonable.  Although iTalkPennyStocks.com can delete messages, you remain solely responsible for the content of your messages, and you agree to indemnify and hold harmless iTalkPennyStocks.com with respect to any claims posted in your messages.  

  • You agree to the use of the Parents Forum for only lawful purposes and those that serve to act as an informational resource to you personally.

  • It is your responsibility to exercise your judgment in evaluating or utilizing any information shared within the discussion forum.  We encourage you to confirm the information shared in the discussion forum before undertaking any action on it.

  • We do not assume any responsibility for any websites or resources that are linked to our site or that you browse as a result of a referral you gained through a link posted on the discussion forum.

  • You can use the Contact us  link on our site to send us comments and/or criticisms regarding content posted and we welcome any feedback related to the content and administration of the discussion forum.  However, we reserve the right to make final decisions on all content posted.

  • If you have questions or concerns about the above stated Disclaimer and Terms of Use of iTalkPennyStocks.com 's Parent Forum, please Contact us .  iTalkPennyStocks.com may make changes to the terms of this agreement on this site. You agree to periodically review this agreement to be aware of any such revisions. Should the revision be unacceptable to you, you agree to stop accessing this site.

  • close

    Join Now! - 100% FREE







    I agree by the terms and conditions